
==== Front
Nat Commun
Nat Commun
Nature Communications
2041-1723
Nature Publishing Group UK London

39266508
52221
10.1038/s41467-024-52221-9
Article
Engineered model of heart tissue repair for exploring fibrotic processes and therapeutic interventions
http://orcid.org/0000-0002-0119-5677
Yang Pengcheng 1
Zhu Lihang 2
Wang Shiya 1
Gong Jixing 3
Selvaraj Jonathan Nimal 1
http://orcid.org/0000-0001-8808-2810
Ye Lincai 4
Chen Hanxiao 5
Zhang Yaoyao 5
Wang Gongxin 6
Song Wanjun 7
Li Zilong 1
http://orcid.org/0009-0005-3605-1429
Cai Lin cailin12@hubu.edu.cn

1
http://orcid.org/0000-0002-0206-9066
Zhang Hao Drzhanghao@yahoo.com

4
http://orcid.org/0000-0002-8128-5874
Zhang Donghui Dongh.zhang@hubu.edu.cn

18
1 https://ror.org/03a60m280 grid.34418.3a 0000 0001 0727 9022 State Key Laboratory of Biocatalysis and Enzyme Engineering, School of Life Sciences, Hubei University, Wuhan, China
2 grid.49470.3e 0000 0001 2331 6153 Department of Biological Repositories, Frontier Science Center for Immunology and Metabolism, Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China
3 grid.12981.33 0000 0001 2360 039X Center of Translational Medicine, The First Affiliated Hospital, Zhongshan School of Medicine, Sun Yat‐Sen University, Guangdong, China
4 https://ror.org/00cd9s024 grid.415626.2 0000 0004 4903 1529 Shanghai Institute for Congenital Heart Diseases, Shanghai Children’s Medical Center, National Children’s Medical Center, Shanghai, China
5 grid.461863.e 0000 0004 1757 9397 Key Laboratory of Birth Defects and Related Diseases of Women and Children of MOE, Department of Pediatrics, West China Second University Hospital, Sichuan University, Chengdu, China
6 Henan SCOPE Research Institute of Electrophysiology Co. Ltd., Kaifeng, China
7 Beijing Geek Gene Technology Co. Ltd., Beijing, China
8 grid.33199.31 0000 0004 0368 7223 Cardiovascular Research Institute, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
12 9 2024
12 9 2024
2024
15 79963 2 2024
30 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc-nd/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
Advancements in human-engineered heart tissue have enhanced the understanding of cardiac cellular alteration. Nevertheless, a human model simulating pathological remodeling following myocardial infarction for therapeutic development remains essential. Here we develop an engineered model of myocardial repair that replicates the phased remodeling process, including hypoxic stress, fibrosis, and electrophysiological dysfunction. Transcriptomic analysis identifies nine critical signaling pathways related to cellular fate transitions, leading to the evaluation of seventeen modulators for their therapeutic potential in a mini-repair model. A scoring system quantitatively evaluates the restoration of abnormal electrophysiology, demonstrating that the phased combination of TGFβ inhibitor SB431542, Rho kinase inhibitor Y27632, and WNT activator CHIR99021 yields enhanced functional restoration compared to single factor treatments in both engineered and mouse myocardial infarction model. This engineered heart tissue repair model effectively captures the phased remodeling following myocardial infarction, providing a crucial platform for discovering therapeutic targets for ischemic heart disease.

Engineered human models of hearts are needed to study pathology and repair. Here, the authors develop a model which replicates the phased remodelling process. The model is then used to study signalling pathway modulators for their therapeutic potential in a mini-repair model.

Subject terms

Phenotypic screening
Arrhythmias
Tissue engineering
https://doi.org/10.13039/501100001809 National Natural Science Foundation of China (National Science Foundation of China) 32171107 Zhang Donghui 1. National Key R&D Program of China, 2021YFA1101902 2. National Key R&D Program of China, 2018YFA0109100National Key R&D Program of China, 2019YFA0110401issue-copyright-statement© Springer Nature Limited 2024
==== Body
pmcIntroduction

Ischemic heart disease (IHD) has affected nearly 197.2 million people globally over the past three decades, resulting in 9.1 million deaths1. IHD mortality arises from arrhythmia or heart failure due to irreversible cardiac muscle damage leading to pathological remodeling2. Following acute myocardial infarction (MI), the overall progression from myocardial injury to complete remodeling can be divided into three phases: death of stressed cardiomyocytes (CM), inflammatory response, and fibrotic scar formation, ultimately impairing myocardial contractility and electrophysiology3. Specifically, proteins released by apoptotic CM4 trigger inflammation, prompting resident cardiac fibroblasts (CF) to differentiate into myofibroblasts (myoCF), which enhances extracellular matrix (ECM) synthesis and collagen deposition in the myocardium scar. Consequently, the injured myocardium is replaced by the dense scar composed of ECM and CF, while surviving CM fails to achieve consistent electromechanical coupling, increasing reentry risk5. The fibrotic scar’s reduced amplitude and slow upstrokes of the action potential cause conduction blocks, with alternative pathways for electrical impulses involved in the re-entry contributing to arrhythmia6.

Human pluripotent stem cell-derived cardiac lineage cells, including CM7, CF8, and endothelial cells9, offer unlimited functional cell sources for fabricating human-engineered heart tissue (hEHT) that adequately mimic the structural and electrophysiological characteristics of adult myocardium10,11. Spherical heart organoids can serve as 3D myocardial tissue to mimic cardiac development and disease12,13. In this respect, Voges et al. found that cryoinjured heart organoids can regain contractility during healing14. Furthermore, Richards et al. developed a heart organoid model of MI by leveraging an oxygen-diffusion gradient, which emulated post-MI pathological features like fibrosis and metabolic shifts15. Despite advancements in the functionality of engineered myocardium and high-throughput drug testing platforms using cardiac organoids, there remains a need for the in vitro model that accurately represents myocardial injury, fibrosis, and electrophysiological dysfunction and allows for quantitative prediction of arrhythmia risk.

Here, we develop a hEHT injury repair model to simulate MI onset, progression, and recovery, focusing on myocardial remodeling. The remodeling process includes an early injury period (days 0–2) characterized by CM apoptosis and structural injury, followed by the fibrotic scar-forming period featuring CF activation (days 2–4). Electrophysiological dysfunction in the remodeled area is observed by day 6, indicated by reduced calcium wave conduction and activity. Transcriptomic analysis through bulk RNA sequencing (bulkRNA-seq) and single-cell RNA sequencing (scRNA-seq) revealed that cAMP, TGFβ1, and ROCK regulated the early injury-induced CM stress and CF mobilization, while the late period involves CM action potential modulation, CF proliferation, and ECM accumulation driven by WNT, PI3K, and NFκB. Also, scRNA-seq underscores the potential transitions of CF during myocardial remodeling. A mini hEHT injury repair model in a 96-well array is further developed to screen seventeen modulators from nine signaling pathways identified from transcriptomic analysis to assess their effects on myocardial remodeling. SB431542 (TGFβ inhibitor), Y27632 (ROCK inhibitor), and CHIR99021 (WNT activator) can prevent excessive fibrosis in the remodeled area. An integrated scoring system encompassing eight electrophysiological parameters evaluates the impact of SB431542, Y27632, and CHIR99021 on electrophysiological dysfunction recovery in the hEHT injury repair model. While Y27632, CHIR99021, and SB431542 partially restore the abnormal calcium activity, only their phased combination effectively rectifies the global electrophysiological dysfunction. The mouse MI model further confirms this phased combination’s superior efficacy in reducing fibrotic area and enhancing cardiac function post-MI. In conclusion, our hEHT repair model can mimic the phased myocardial remodeling and elucidate post-MI electrophysiological dysfunction, enabling rapid screening for potential anti-fibrotic and cardiac regeneration drug targets for the IHD treatment.

Results

Establishment of the hEHT injury repair model in vitro

Dissociated hPSC-derived cardiomyocytes (hPSC-CM) were encapsulated in fibrin-Matrigel hydrogel to form 7 × 7 mm hEHTs11. The hEHTs spontaneously and rhythmically contracted after 3 days of culture (Supplementary Movie 1). Owing to its reproducibility, cryoinjury has been used to model MI in mice16, pigs17, and human cardiac organoids13,14. To establish a standardized humanized myocardial injury repair model using hEHT (Fig. 1a), we designed and tested cryoinjury devices A, B, and C, differentiated by conical tip sizes (Supplementary Fig. 1a). These devices were used with a polydimethylsiloxane (PDMS) pedestal (Supplementary Fig. 1b) to assist cryoinjury device in localization and penetration of hEHT (Supplementary Fig. 1c). The tips were pre-cooled in liquid nitrogen to induce four cryoinjured areas per hEHT (Supplementary Fig. 1d). Blunter tips from devices A and B resulted in larger, more heterogeneity injury area (Supplementary Fig. 1e, f), occasionally leading to irreversible hEHT rupture (Supplementary Fig. 1g). Conversely, Device C, with its sharpest tip, produced a more consistent initial cryoinjured area (Supplementary Fig. 1e, f) without affecting hEHT spontaneous beating (Supplementary Movie 2). The initial cryoinjured area enlarged on day 1, increasing to the maximum on day 2. Between days 2 and 6, the enlarged cryoinjured area progressively remodeled (Fig. 1b, c), reflecting a phased remodeling of cryoinjured hEHT.Fig. 1 Establishment of hEHT injury repair model.

a Schematic overview of the remodeling response of cryoinjured hEHT. b Representative phase-contrast images showing the remodeling in the cryoinjured area. Dotted lines outlined the initial cryoinjured area. Scale bar, 250 μm. c Quantification of the cryoinjured area over time. (n = 18 areas from 3 independent experiments). d Immunostaining for CM (SAA+), myoCF (αSMA+), and apoptotic cells (TUNEL+) at days 2 and 4 demonstrated the dynamics of CF in the remodeling of cryoinjured hEHT. Scale bar, 200 μm. Inside the white dashed circle was the remodeled area (RA), and outside was the uninjured area (UA). e TUNEL+ cells variation in RA and UA on days 2 and 4 after cryoinjured. n = 20 areas from 3 independent experiments. f Differences in the length of the stress fiber located in αSMA+ cells in RA and UA of cryoinjured hEHT at days 2 and 4. n = 60 stress fibers in 6 areas from 3 independent experiments. g Representative immunofluorescence staining images of the cardiac cell (VIM, SM22α, cTNT) and ECM markers (Collagen I and Fibronectin) characterizing both RA and UA at day 6 after the hEHT cryoinjured. Scale bar, 200 μm. h The difference in the fluorescent intensity of cardiac cell markers (VIM, SM22α, cTNT) and ECM markers (Collagen I and Fibronectin) between UA and RA. Each marker was normalized to the fluorescence intensity of DAPI. (VIM, n = 15 areas; SM22α, n = 19 areas; cTNT, n = 33 areas; Collagen I, n = 24 areas; Fibronectin, n = 15 areas). Data are presented as mean ± SEM in (e), (f), and (h). p values were calculated by Sidak’s multiple comparisons test in (e) and (f), and two-sided unpaired t-test in (h).

Regional cell apoptosis and reactive oxygen species production are the critical initial events in myocardial remodeling post-MI18. We observed a significant increase in TUNEL+ cells (Supplementary Fig. 2a, b) and ROS production (Supplementary Fig. 2c, d) around the cryoinjured area on day 2. Destruction of the CM structure was observed by cTNT staining, reflecting the stress status of cryoinjured hEHT in the first two days post-injury (Supplementary Fig. 2e). Notably, only the cryoinjury but not puncture can induce dramatic cell apoptosis (Supplementary Fig. 2f, g) and ROS accumulation (Supplementary Fig. 2h, i) around the injured area. During remodeling, the TUNEL+ cells in the remodeled area significantly declined to normal levels by day 4 (Fig. 1d, e). The presence of CM (SAA+, MYH+), CF (VIM+ and SM22α+), and myoCF (αSMA+) was observed in normal hEHT11 (Supplementary Fig. 2j). As known that αSMA+ myoCF play a significant role in myocardial remodeling, a substantial increase in αSMA expression localized in the stress fiber was found on days 2 and 4 of the remodeling (Fig. 1d, f). Hence, the remodeling of the cryoinjured hEHT can be divided into an early injury expansion phase (days 0–2) with cellular stress followed by CF activation phase (days 2–4). By day 6, the fibrotic scar in the remolded area was observed (Fig. 1g), resembling the early stress and late fibrosis post-MI19.

To visualize the remodeling in the hEHT injury repair model, we performed time-lapse imaging of hEHTs generated from hPSC-CM, while marking the whole population with mCherry lentivirus and marking CM with TNNT2-GCaMP5, such that non-CM fluoresce red and CM fluoresce green and red (Supplementary Movie 3). A spiral migration of non-CM along the edge of the cryoinjured area to refill the injured area was observed. Post-MI, CF differentiates into myoCF, followed by enhanced ECM synthesis with increased collagen I and III deposition in the fibrotic scar20. As observed in our model, the remodeled areas were similarly characterized by the differential number of CF (VIM+ and SM22a+), with an increase in type I collagen and more fibronectin at day 6, along with fewer CM (cTNT+) (Fig. 1g, h). However, this fibrotic scar had no disruptions in the overall spontaneous beating of hEHT (Supplementary Movie 2). The above results demonstrated that our model could mimic the post-MI events, highlighting the major role of CF, which migrates from the edge of the injured area to the central injured region and secreted ECM to refill the injured area in the late scar-forming period21.

hEHT injury repair model exhibited arrhythmic-related electrophysiological malfunction post-fibrotic scar formation

MI frequently precipitates arrhythmias by impairing CM function and inducing fibrosis, which impedes cardiac electrical signal propagation22. Utilizing cardiac optical mapping with calcium-sensitive dye, we performed optical mapping on remodeled hEHTs (Fig. 2a and Supplementary Movie 4) to investigate tissue-level calcium wave propagation abnormalities around the remodeled areas on day 6 post-injury (Fig. 2b). Compared to uninjured areas, the remodeled area exhibited decreased calcium wave conduction velocity and increased directional propagation inhomogeneity owing to the fibrotic scar (Fig. 2c, d). In addition, calcium transients within the remodeled area had significantly lower amplitude, maximum upstroke velocity, and maximum recovery velocity, reflecting the diminished calcium signal in the remodeled area (Fig. 2e–g). Prolonged 50% and 80% of calcium signal duration (CSD50 and CAD80), and extended depolarization and repolarization activation times in the remodeled area were also noted (Fig. 2h). Our findings revealed that increased refilling of CF than CM in the remodeled area created an abnormal calcium activity, leading to a conduction block. These areas of slow conduction or conduction block will increase the risk of triggering reentrant arrhythmias in the whole hEHT (Supplementary Movie 5)23. Corresponding studies in rat model of MI exhibited similar electrophysiological dysfunctions (Supplementary Fig. 3a). Specifically, the decline in calcium signal propagation velocity and directional homogeneity within the infarct area were observed (Supplementary Fig. 3b, c). The malfunction reflecting the changes in calcium signal waveform characteristics in the MI rats was similar to the remodeled hEHT (Supplementary Fig. 3d–f), emphasizing that the hEHT repair model can exhibit the process of injury onset, fibrosis development, and regionalized malfunction together to mimic the spatiotemporal landscapes of MI.Fig. 2 Regional calcium activity abnormalities in remodeled hEHT.

a Representative time-lapse images showed calcium wave propagation in both uninjured (UA) and remodeled areas (RA). b Representative spatial map of the four remodeled areas in hEHT presenting the difference in calcium activity between the UA and RA. Initial cryoinjured areas are marked in circles. The white triangle represented the electrical stimulation origin (1 Hz). The representative RA was marked as a red box, and the UA was marked as a blue box. Scale bar, 1 mm. c Enlarged spatial maps of UA and RA (20 × 20 pixels) were represented as the box in (b). Calcium signal conduction velocity and direction were labeled by the colorized arrows. Scale bar, 200 μm. d Differences in calcium signal conduction velocity and direction homogeneity between UA and RA. n = 8 areas from 3 independent experiments. e Existence of abnormal continuous calcium signal in the remodeled area. The representative stripe image showed the time course of the calcium signal in the black line shown in (b) that passed the uninjured and remodeled areas, with waveform representing the average calcium signal during 10 seconds of representative dots (3 × 3 pixels, labeled by a, b, c located in UA and RA in (b)). f The schematic diagram outlined parameters for evaluating the waveform characteristics of the calcium signal. g Differences in amplitude, maximum upstroke velocity, and maximum recovery velocity of calcium signal between UA and RA. n = 8 areas from 3 independent experiments. h Differences in 50% CSD, 80% CSD, T maximum upstroke velocity, and T maximum recovery velocity of calcium signal between UA and RA. n = 8 areas from 3 independent experiments. Data are presented as mean ± SEM in (d), (g), and (h). p values were calculated by two-sided unpaired t-test in (d), (g), and (h).

hEHT injury repair model exhibited differential gene expression between the early and late periods of remodeling

We conducted bulkRNA-seq to further characterize the remodeling of injured hEHT by comparing cryoinjured (Cryo) and control (Con) hEHTs during the injury expansion (day 2, “Early”) and scar-forming (day 4, “Late”) periods (Supplementary Fig. 4a). Principal component analysis (PCA) revealed significant gene expression difference between these groups (Supplementary Fig. 4b). The comparison between Cryo and Con identified 1147 differentially expressed genes (DEGs) at day 2 and 556 DEGs at day 4 (Supplementary Fig. 4c). Notably, 151 DEGs were common across early and later periods, primarily enriched in terms related to response to hypoxic response and apoptosis regulation (Supplementary Fig. 4d). This included significant upregulation of hypoxic stress-related genes NDRG124 and anti-apoptotic genes FAIM225, demonstrating a collaborative anti-apoptotic response over time (Supplementary Fig. 4d) and correlating with decreased apoptosis from early to late period (Fig. 1d–f).

In the early period, the top 15 enriched Biological Process Gene Ontology (GO) terms for DEGs were mainly associated with response to hypoxia response, angiogenesis, and cell differentiation (Supplementary Fig. 4e). Conversely, the DEGs in the late period focused on CM’s action potential, cardiac contraction, and cell proliferation regulation (Supplementary Fig. 4e). KEGG pathway analysis suggested that DEGs in early and late periods were enriched for distinct signaling pathways, with MAPK, cAMP, and HIF-1 signaling prevalent in the early period, and TNF, NFκB enriched in the late period (Supplementary Fig. 4f), demonstrated that even shared GO terms like ECM organization, apoptosis regulation, cell adhesion, and inflammatory response (Supplementary Fig. 4e) were modulated by different signals during the remodeling of injured hEHT. These findings underscore the notable phenotypic differences between early and late periods of the remodeling process within the hEHT injury repair model, evidenced by increased ROS accumulation and cell apoptosis in the early period (Supplementary Fig. 2a–d), and CF activation (Fig. 1d–f), ECM deposition (Fig. 1g, h) in the late period.

hEHT injury repair model exhibited diversified cellular composition during remodeling

To elucidate cellular and signaling dynamics during repair, we performed scRNA-seq on Cryo and Con hEHT at Early and Late time points (Supplementary Fig. 4e). For both Cryo and Con groups, we identified four main cell types-CM, CF, epicardial cells (EP), and endothelial cells (ED) (Fig. 3a)-based on cell clustering followed by automatic annotation and expression of known cellular marker genes in the human heart (Supplementary Fig. 5a, b, Supplementary Table 2). Further debatching was performed using Harmony, and the data reached convergence after 4 iterations of flexibility, yet no injury-specific clusters emerged (Supplementary Fig. 5c, d). Meanwhile, the UMAP plots separated across varying groups illustrating cryoinjury didnot yield new cell subpopulation (Fig. 3a, b).Fig. 3 Transcriptomic analysis underlying the subcellular composition and signaling dynamics during the remodeling of injured hEHT.

a UMAP plot showing the four main cell clusters from scRNA-seq of control and cryoinjured hEHT at early and late periods. b Feature UMAP plots demonstrating the four cell clusters in each group. c UMAP plot showing the four CM subpopulations in control and cryoinjured hEHT at early and late periods. d Heatmap showing Z score scaled average DEG expression in each CM subpopulations with top GO terms presented. e Feature UMAP plots of DEGs in four CM subpopulations. f Violin plots for sarcomere-related gene expression in four CM subpopulations. g UMAP plot showing five CF subpopulations in control and remodeled hEHT at early and late periods. h Heatmap showing Z score scaled average DEG expression across five CF subpopulations with top GO terms presented. i Feature UMAP plots for DEGs in five CF subpopulations. j Immunostaining of CD44, CXADR, and VIM in remodeled hEHT to reveal the different distribution of CF4 (VIM+/CD44+/CXADR−) and CF5 (VIM+/CD44+/CXADR+) in UA and RA. Scale bar, 200 μm. k Representative line graph reflecting changes in fluorescence intensity (normalized to the gray value of DAPI) of CD44, CXADR, and VIM from UA to RA in (j). l, m Violin plots showing representative DEG expression levels in four CM and five CF subpopulations from control and cryoinjured hEHT at early and late periods. p values were calculated by modified Fisher’s Exact test in (d) and (h), and two-sided unpaired t-test in (l) and (m).

Changes in cell states are pivotal for the in vivo cardiac response following MI, encompassing cell stress, metabolic shift, CM dysfunction, and CF activation26. To analyze CM and CF state shifts following cryoinjury, we subclustered these cell types across early and late remodeling periods, revealing four distinct CM subpopulations (CM1-CM4) (Fig. 3c–f) and five distinct CF subpopulations (CF1-CF5) (Fig. 3g–i) existed in both Cryo and Con hEHT. All CM subpopulations expressed sarcomere-related genes (MYH6, MYH7, TTN, MYH7B), but albeit at varying expression levels, with CM1 showing the lowest, particularly for MYH7 expression, which is the predominant isoform in the adult heart27. The MYH6/MYH7 ratio signifies the transition of sarcomere components from fetal to an adult isoform27, with CM1 displaying the lowest ratio and expressing cardiac development markers such as BMP428, highlighting its fetal traits (Fig. 3d–f). CM2 and CM3 shared similar sarcomere-related gene expression levels (Fig. 3e, f), whereas CM2 stood out with metabolic-related genes, including nuclear-encoded mitochondrial genes (NDUFA4, NDUFB11, COX7C, and COX5B), and the antioxidant gene CRYAB (Supplementary Fig. 6a, b), indicating CM2 as a high-energy subpopulation found in the adult heart29. CM4 highly expressed division-associated genes (MKI67, CDK1) (Fig. 3d, e) suggested its possible role in regenerative repair30.

Recent studies have identified multiple CF subpopulations in both healthy and diseased hearts31, crucial for myocardial remodeling. Similarly, five CF subpopulations (CF1, CF2, CF3, CF4, and CF5) were identified in the hEHT injury repair model (Fig. 3g). CF1 specifically overexpresses cell division-related genes, like MKI67, suggesting its proliferative subpopulation (Fig. 3h, i). CF2 exhibited significant expression of stress fiber markers ACTA2, characteristic of myoCF (Fig. 3h, i). CF3 showed enrichment in ECM organization and cell adhesion GO terms, with a high expression level of HTRA332, known for maintaining CF quiescence (Fig. 3h, i). Intriguingly, CF5 expressed classical CF markers33, such as DCN and LUM (Fig. 3i and Supplementary Fig. 5b), while also expressing markers associated with epithelial cell development, like UPK3B34, and CXADR (Fig. 3h, i). Both CF4 and CF5 highly expressed CD44 (Fig. 3i), a cell-surface glycoprotein encoding gene that can regulate CF function following MI35. In particular, DEGs in CF4 were mainly associated with epithelial-mesenchymal transition, indicating the transition status of CF4 between epicardial-like CF5 and other CF subpopulations. we further found that the VIM+/CD44+/CXADR- CF, that is, CF4, accumulated in the remodeled area (Fig. 3j, k), whereas VIM+/CD44+/CXADR+ CF5 appeared only in the uninjured area (Fig. 3j, k), indicating a potential transition from epicardial-like CF to myoCF in myocardial remodeling.

The postnatal epicardium typically remains quiescent36 but can reactivate following cardiac injury, leading to the upregulation of WT1 and EMT marker genes such as TBX18 or SNAI137. Upon injury, EP undergoes epithelial-to-mesenchymal transition and migrates to the injured area, contributing to post-injury repair38. Notably, the EP in the hEHT injury repair model, immunostained by WT1, predominantly localized in the surface layer of hEHT, similar to the structural composition of myocardium in vivo, and also can contribute to the remodeled area (Supplementary Fig. 6c), indicating that EP migration might enhance repair post-injury. Meanwhile, some Tie1+ EC were irregularly distributed between uninjured and remodeled areas (Supplementary Fig. 6d), implying both EP and EC play roles in scar formation within our model, supported by animal models evidence39. In addition to altering the spatial distribution of cell subpopulations, cryoinjury also led to a decrease in the total number of cells captured by scRNA-seq in hEHT (Supplementary Fig. 6e). Specifically, cryoinjury elevated the percentage of immature CM (CM1, CM2) and inactive CF (CF4, CF5), while all other cell subpopulations decreased in the early period (Supplementary Fig. 6e). This trend was completely reversed in the late period, with an increase in activated CF1, CF2 and also in proliferating CM3 (Supplementary Fig. 6e), which was consistent with the presence of different proportions of CF and CM in the remodeled area (Fig. 1g, h).

Signaling dynamic shift of different cell subpopulations in hEHT injury repair model

To explore the injury response of CM subpopulations, GO and KEGGs analysis of DEGs between Cryo and Con hEHT indicated that in the early period, primarily CM1 and CM4 underwent oxidative stress processes (Supplementary Fig. 7a), akin to the enriched gene ontology observed in bulk RNA-seq analysis, featuring genes SOD140 (Fig. 3l), PON241, PXDN42 (Supplementary Fig. 7b). In the late period, enhanced metabolism and sarcomere remodeling were predominantly observed in CM2 and CM3, indicated by genes DIO343 and ARF1 (Supplementary Fig. 7c, d). Additionally, WNT signaling pathway genes like FRZB44 (Fig. 3l), and TMEM8845, exhibited differential regulation, being upregulated in the early and downregulated in late periods (Supplementary Fig. 7b, d). This suggested that the enhanced oxidative metabolism and functional recovery in CM2 may be modulated differently by the WNT signaling pathway during the remodeling. Moreover, transcription factor (TF) analysis indicated that upregulated TFs in four CM subpopulations correlated with hypoxic stress (STAT5A46, BHLHE40) and anti-apoptosis (E2F6, E2F8, NFE2L1) in the early period (Supplementary Fig. 8a, b). TFs associated with cardiac development regulation (ETS1, SP247, MSX2) and CM proliferation (E2F7, E2F8) were more pronounced in the late period (Supplementary Fig. 8c, d), highlighting the role of stress in activating the intrinsic regenerative potential of CMs in the hEHT injury repair model.

The DEGs of CF were enriched in the TGFβ, MAPK, PI3K, and RHO signaling pathways (Supplementary Fig. 9a) in the early period, which were also identified in bulkRNA-seq. Notably, CF3 stood out with more DEGs, including TGFB1 (Fig. 3m) and RHOB48 (Supplementary Fig. 9b), both related to CF activation and proliferation. As myoCF, CF2 showed elevated ACTA2 expression in the cryoinjury group, indicating heightened myoCF activation initiation in the early period for further scar formation in the late period (Fig. 3m). In the late period, CF in the cryoinjured group exhibited increased expression related to proliferation (CCNB249, LOX50) and PI3K signaling pathway (CREB3L151) (Fig. 3m and Supplementary Fig. 9d). Most CF subpopulations, apart from CF5, also showed elevated collagen secretion-associated genes, such as COL1A1, COL1A2, and TIPM2 (Fig. 3m and Supplementary Fig. 9d).

TF analysis for the CF subpopulation showed that the levels of proliferation-associated TFs E2F752, E2F8, and E2F153 were decreased in proliferative CF1 in the early period (Supplementary Fig. 10a, b) but then increased in the late period (Supplementary Fig. 10c, d). Similarly, CF4 and CF5 highly expressed TF associated with cell fate transition in the early period, such as PBX454 and FOSL255 (Supplementary Fig. 10a, b), but had lower expression of MSX1 in the late period (Supplementary Fig. 10c, d), indicating that the injury-induced fate transition in inactive CF was progressively attenuated and eventually contribute to fibrosis. These findings indicated that the cryoinjury prompted CF to transition to a more active state characterized by enhanced cell proliferation and increased secretion of ECM components during the late period of the remodeling in the hEHT injury repair model, which mirrored the scar maturation process observed in vivo56.

CF fate transition and interaction with CM in hEHT injury repair model

CF plays a critical role in pathological myocardial remodeling, leading us to investigate its fate transitions during injury repair. Pseudotime analysis identified two lineage trajectories: cell fate 1 from CF5 to CF1 and cell fate 2 from CF5 to CF3 (Supplementary Fig. 11a, b). Three gene sets were identified to modulate the cell fate transitions (Fig. 4a), including gene set 1, which was enriched in terms related to cell fate determination, oxidative stress, and WNT, Rho signaling pathways to promote cell fate 2 from CF5 to CF3. Gene set 3, which enriched for BMP, TGFβ, and MAPK signaling pathways, dominated the transition from CF5 to CF1 (Fig. 4b). Specifically, in gene set 3, the cytoskeleton-related genes SIPA1L1 and ACTA2 increased in cell fate 1 but decreased in cell fate 2, while the ECM-related genes POSTN and COL1A1 exhibited opposite patterns (Supplementary Fig. 11c), indicating the differential modulation in CF fate. To validate the in vivo relevance of CF fate transition, we further referenced the scRNA-seq data from the clinical heart with dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM) hearts31 (Supplementary Fig. 11d). Clustering and pseudotime analysis revealed that the quiescent CF in human MI hearts similarly transitioned to myoCF or contractile CF (Supplementary Fig. 11e, f), regulated by TGFβ, WNT, PI3K, and ERK signaling (Supplementary Fig. 11g). The CF in hEHT repair model exhibited similar fate transition patterns, with dynamic gene expression related to TGFβ signaling (JUN, FOS, COL3A1), ECM (ADAMTS1, COL16A1, MMP28), and stress response (COL1A1, BTG, FOSB) as in vivo (Fig. 4c, d).Fig. 4 Pseudotime analysis revealed that CF in the hEHT injury repair model exhibited similar cell fate transitions in vivo.

a Heatmap displaying significantly altered genes at the transition node from epicardial-like fibroblasts (CF5) to quiescent fibroblasts (CF3) or proliferative fibroblasts (CF1). The black line indicated the gene expression change from CF5 to CF3, while the pink dashed line depicted the change from CF5 to CF1. The color gradients from blue to red indicate the relative gene expression level from low to high. b Top 10 GO terms of significantly altered gene set (different colored frames in (a)) in pseudotime trajectory. c Spline plots illustrating representative genes changed in the two CF transition trajectories within the hEHT injury repair model. d Comparison spline plots for the same genes in (c), showing changes in two CF transition trajectories in clinical dilated cardiomyopathy (DCM) and ischemic cardiomyopathy (ICM) hearts (GEO: GSE145154), where the black line indicated the gene expression change from quiescent CF to contractile CF, and the pink dashed line indicated the change from quiescent CF to myoCF.

Given CF’s highly plastic and dynamic nature, cell interaction analysis at both the major (Supplementary Fig. 12a) and subtype level (Supplementary Fig. 12b) revealed a notable alteration in the number of CF-CM interactions post-cryoinjury, especially between CF2/CF5 and CM, except mature CM3 (Supplementary Fig. 12c). To focus on the most representative interactions, the injury-specific cell interactions between CF and CM were further investigated at the subpopulation level (Supplementary Fig. 12d). In the early period of remodeling, the APOA2_ABCA1 interaction was enhanced between CF2/5 and CM2/4, which is known to regulate CM metabolism57. The cryoinjury also strengthened interactions between CF5 and immature CM1/2 or proliferating CM4 via NRXN2_DAG1 (Supplementary Fig. 12e), which can promote CM proliferation58. CF2 continuously expressed TGFB1 to induce CM stress59 in both the early and late period (Supplementary Fig. 12e). Meanwhile, the detrimental effects of CF2 on CM were evidenced by the increased expression of THBS1 in the late period (Supplementary Fig. 12e), which can trigger CM autophagy60. Conversely, FB5 exhibited a protective effect through increased DKK1_LRP6 interaction with CM (Supplementary Fig. 12e), leading to the inhibition of CM apoptosis61. The above scRNA-seq analysis demonstrated the dynamic cellular orchestration during remodeling of cryoinjured hEHT, especially in CF. These cellular dynamics were mainly dominated by serious signaling pathways such as TGFβ, WNT, RHO, PI3K, NFκB, and MAPK, which allowed us to gain a deeper understanding of the underlying mechanisms of myocardial pathological remodeling.

A mini hEHT-injury repair model for rapid screening of potential therapeutic targets for IHD

We developed a mini hEHT-injury repair model with a diameter of approximately 4 mm to expedite the evaluation of potential therapies against myocardial pathological remodeling. Utilizing 3D printing, we fabricated a mini-hEHT similar in shape to skeletonized 8-strip PCR tubes (Fig. 5a). A pedestal with a 0.3 mm diameter stainless steel needle (Fig. 5b) enabled batch, uniform cryoinjury in each mini-hEHT (Fig. 5c). Notably, the mini hEHT response to cryoinjury was consistent to that in hEHT. The injured area initially expanded in the early period (days 0–1) and began shrinking during the late period (days 1–5) (Fig. 5e, f), revealing a regionalized fibrotic area consisting of less CM and primarily populated by CF (Fig. 5g).Fig. 5 Establishment of the mini hEHT-injury repair model.

a Three views drawing and image of the device for batch fabrication of mini-hEHT: x, z-view (top left); x, y-view (lower left); y, z-view (right). b Three views drawing and image of the pedestal for batch cryoinjury in mini-hEHT repair model: x, y-view (top left); x, z-view (lower left); y, z-view (right). c Photos of cryoinjured mini-hEHT. The white arrow indicated the cryoinjured area on the cryoinjured mini-hEHT. d Schematic of the mini hEHT-injury repair model for screening potential therapeutic targets of IHD. e Representative phase-contrast images and enlarged views of cryoinjured area remodeling in mini-hEHT- injury repair model. Scale bar 500 μm, 200 μm for enlarged views. f Quantification of individual cryoinjured area changes during remodeling in cryoinjured mini-hEHT. n = 15 remodeled mini-hEHTs from 3 independent experiments. g Representative confocal images and enlarged views of cardiac cell markers (cTNT for CM, TE7 for human CF) in single remodeled mini-hEHT. Scale bar 500 μm, 200 μm for enlarged views.

Using the mini hEHT- injury repair model, we can evaluate the pro-repair of seventeen modulators from nine signaling pathways (Fig. 5d) identified from the bulkRNA-seq and scRNA-seq analyses (Supplementary Fig. 13a). Variation in the remodeling rate of cryoinjured mini-hEHT was first observed (Supplementary Fig. 13b), bFGF, Y27632, SB431542, 740YP, LY294002, and DMU212 significantly accelerated the remodeling (Supplementary Fig. 13c). Specifically, bFGF and LY294002 expanded the cryoinjured area in the early period, completing remodeling by day 4, while DMU212, 740YP, SB431542, and Y27632 directly shortened healing time to day 3 (Supplementary Fig. 13c, d). Thus, these interventions accelerated remodeling in different approaches, suggesting that they influenced remodeling outcomes by regulating CM or CF individually in the hEHT injury repair model.

Multidimensional evaluation of the effect of different signaling modulators on mini hEHT remodeling outcomes

We further developed a quantitative assessment strategy to analyze the effects of these modulators on CM and CF in the remodeled area by analyzing 3D images of the mini-hEHTs stained with CM and CF markers on day 6 (Supplementary Fig. 14a, Supplementary Movies 6 and 7). By subtracting the CM’s absence area from the maximum cryoinjured area at each Z-axis layer (Supplementary Fig. 14a, b), we can estimate the percentage of CM volume inside the remodeled for further comparison. We also assessed the CM eccentricity degree to gauge CM contribution to remodeling and measured CF stress fiber length to evaluate CF activation. (Supplementary Fig. 14c). Control experiments ruled out DMSO interference with these metrics (Supplementary Fig. 14d–f). With these three outcome measures, we then scored the impact of seventeen signaling modulators on mini-hEHT remodeling (Fig. 6a).Fig. 6 The evaluation of treatment effects on the mini hEHT-injury repair model.

a Representative confocal images of CM and CF in the remodeled area of cryoinjured mini-hEHT under various treatments. Scale bar, 200 um. b Correlation analysis between the volume share of CM and the CM’s eccentricity degree in the remodeled area. n = 200 from different groups. c Correlations analysis between the volume share of CM and CF’s stress fiber length in the remodeled area. n = 100 from different groups. d Integrative ranking plots based on the mean values of CM’s volume share, CM’s eccentricity degree, and CF’s stress fiber length under various treatments.

Among the seventeen candidates, CHIR99021, SCH772984, and Y27632 significantly increased CM fractional volume in the remodeled area from 40% in the control to over 60% (Supplementary Fig. 14g) and simultaneously reduced CM eccentricity (Supplementary Fig. 14h), indicating the beneficial effect on structural remodeling outcome. As for the impaction on CF, TGFβ1 significantly increased stress fibers length (Supplementary Fig. 14i). At the same time, PDTC, NS398, CHIR99021, SQ22536, 740YP, LY294002, and SB431542 inhibited CF activation (Supplementary Fig. 14i). Correlations among CM eccentricity, CF stress fiber length, and CM proportion in the remodeled area (Fig. 6b, c) suggested that CM and CF interact to influence structural outcomes. The overactive CF may prevent CM migration to the cryoinjured area, decreasing their proportion in the remodeled area. Thus, the multidimensional evaluating system based on these three interrelated indices, i.e., CF activation, CM eccentricity, and CM fractional volume in the remodeled area, identified Y27632, CHIR99021, and SB431542 possessed leading benefits on both myocardial regeneration and anti-fibrosis over other treatments (Fig. 6d).

Integrative scoring system to evaluate the functional recovery in the remodeled area

To understand the structural and electrophysiological shift clearly, we utilized the hEHT injury repair model to assess the effect of Y27632, CHIR99021, SB431542, and their combination (Fig. 7a). Consistent with the screen results based on mini-hEHT, Y27632, and CHIR99021 narrowed down the CM eccentricity and increased the CM volume fraction in the remodeled area (Supplementary Fig. 15a–d). SB431542 exhibited the most significant inhibition of CF activation but had only a tendency to increase CM volume fraction. In contrast, the phased combination of Y27632, CHIR99021, and SB431542 increased the CM volume fraction and inhibited fibrosis in the remodeled area (Supplementary Fig. 15a–d).Fig. 7 The integrative evaluation of treatment effects on the recovery of abnormal calcium activities in the hEHT repair model.

a Flowchart comparing single-factor and combination treatment on remodeling in cryoinjured hEHT. b Representative spatial maps showing RA under varying electrical stimulation and ISO loads (1 Hz stimulation with or without ISO and 1.5 Hz stimulation with ISO). Calcium signal conduction velocity and direction were labeled by the colorized arrows, with each area containing 20×20 pixels. c Quantitative analysis of abnormal calcium activity areas from spatial maps across different loading conditions. n = 10 remodeled areas from 3 independent experiments. Scores for different treatments under 3 load conditions are represented with varying-colored numbers; higher scores reflect better recovery. d Differences in the calcium signal conduction velocity and direction homogeneity of calcium signal propagation in the remodeled areas under different loading conditions. n = 10 remodeled areas from 3 independent experiments. e Representative calcium signal waveforms in the remodeled area under varying loading conditions. f Quantification of the amplitude and CSD80 of calcium signal in the remodeled areas under different loading conditions. n = 10 remodeled areas from 3 independent experiments. g Integrative ranking charts for 8 parameters of calcium activities in remodeled areas under different treatments versus the uninjured area in the control group. Increased green intensity means the closer the corresponding parameter to the criterion, with scores ranging from 1 (yellow) to 5 (green) as the number shown in (c)–(f). Data are presented as mean ± SEM.

Calcium activity abnormalities manifested as disrupted calcium signal conduction, driven by non-functional CF accumulation. We further evaluated the effect of these modulators on calcium activity (Supplementary Movie 8) in the hEHT injury repair model. We quantified the regional blockage of calcium wave conduction at baseline and under stimulation by isoproterenol (ISO) or increased electrical pacing (Fig. 7b). Only the phased combination of Y27632, CHIR99021, and SB431542 reduced the regional conduction block under three loading conditions (Fig. 7c). Moreover, the combination group can partially improve the calcium signal conduction homogeneity in the remodeled area, while largely restoring conduction velocity to normal level (Fig. 7d), where CHIR99021 uniquely enhancing conduction homogeneity under three loading conditions (Fig. 7d). Compared to uninjured areas, remodeled area exhibited reduced calcium signals across all conditions, with no treatment restoring this attenuation (Fig. 7e). The combination and CHIR99021 treatment could relatively rescue the most calcium activity parameters, represented by calcium signal amplitude and CSD80, to a normal level similar to that of the uninjured area in the control group (Fig. 7f).

To develop an integrative scoring system, an abnormal function area and ten parameters related to the calcium signal propagation or calcium signal wave were applied to evaluate the global characteristics of calcium activity in the remodeled area. Treatment rankings emerged from comparing the mean values of parameters with those in the uninjured area of the control group. The smaller the difference, the higher the ranking and the higher the score (Fig. 7d-f). To prevent similar highly correlated parameters from skewing scores62, we analyzed the correlation among ten parameters derived from the calcium conduction and signal waveform (Supplementary Fig. 15e). The resulting heatmap revealed that maximum upstroke and recovery velocity correlated most significantly with calcium signal amplitude. In addition, CSD80 and CSD50 had higher correlations due to their similar definitions, so the redundant parameters were removed from the composite scoring system (Supplementary Fig. 15e). Ultimately, our final integrative scoring system comprised eight informative parameters to evaluate treatment effects on functional recovery. This integrative scoring system demonstrated that the combination of Y27632, CHIR99021, and SB431542 effectively reduced abnormal functional areas (Fig. 7c), while also having the optimal effect in restoring conduction velocity, conduction direction homogeneity, and calcium signal amplitude and CSD, to achieve the highest scores across three loading conditions (Fig. 7g).

BulkRNA-seq revealed the antifibrotic/cardiac repair effects of Y27632/CHIR99021/SB431542

Given the significant effect of the combination treatment in promoting functional repair of injured hEHT, we performed bulkRNA-seq on CM and CF in cryoinjured hEHT sequentially treated with Y27632, CHIR99021, and SB431542 and in control hEHT correspondingly treated with DMSO (Supplementary Fig. 16a). PCA clustering analysis revealed distinct effects of these interventions on CM and CF (Supplementary Fig. 16b, c), with downregulation of LIMK2 and upregulation of LEF1, the downstream effector of ROCK and WNT signaling, and direct downregulation of TGFβ1 indicating the efficacy of the intervention at the corresponding target signaling (Supplementary Fig. 16d). Compared to Y27632 and SB431542, CHIR99021, applied during days 2–4 post-injury, yielded greater effects on both CM and CF (Supplementary Fig. 16e). These interventions also induced common effects, such as leading to the upregulation of STC1 in CM (Supplementary Fig. 16f), making it more antioxidant. Meanwhile, the sustained upregulation of TDO263 (Supplementary Fig. 16f) after the CHIR99021 treatment was shown to be cardioprotective.

Furthermore, Y27632 treatment specifically downregulated CHAC264 expression in CM to reduce ROS, while the specific upregulation of GPER165 can protect CM from various stressors (Supplementary Fig. 17a). Y27632 activated the pyruvate metabolism (LDHA, SLC2A1, HK2), enhanced the protection against hypoxic stress (NDNF, STC1), and increased prostaglandin synthesis (PTGDS, PTGES) in CM and CF (Supplementary Fig. 17a), demonstrating its potential role in metabolic reprogramming under stress. Additionally, the specific upregulation of ACKR366 and UCP267 in CF is cardioprotective (Supplementary Fig. 17a).

CHIR99021 treatment reduced the expression of the ferroptosis-related gene ALOX1568 in CM while increasing the expression of the cardioprotection-related gene SSTR269, and also activation of C5AR170, which can promote cardiomyocyte proliferation after cardiac injury (Supplementary Fig. 17b). The consistent changes in ERK1/2 signaling-related genes (NPY, KDR, CD44, FGF19) in CM and CF, especially CD44 as a marker distinguishing between epicardial-like CF5 and transitional CF4, which was regionally highly expressed within the cryoinjured hEHT contributing to fibrotic scar formation (Fig. 3g, h) and was downregulated in the CHIR99021 group (Supplementary Fig. 17b). Meanwhile, a series of pro-inflammatory and pro-fibrotic mediators such as IL1B, IL34, IL17RE, SPP1, and MMP9 were downregulated in the CHIR99021 group (Supplementary Fig. 17b). The most studied MMP971 will promote adverse cardiac remodeling post-MI, while it was upregulated in both early and late remodeling periods of cryoinjured hEHT (Supplementary Fig. 4d). Interestingly, CHIR99021 also specifically upregulated NPNT72 in CF, a gene associated with pro-cardiomyocyte division, and TBX573, a gene associated with promoting CF reprogramming to CM (Supplementary Fig. 17b).

SB431542 treatment significantly downregulated ECM synthesis genes in CM, such as TGFB1, COL1A1, COL5A1, ADAMTS8, and SMOC2 (Supplementary Fig. 17c), while the upregulation of EPO74 was shown to play a critical protective role post-human MI. In addition to directly downregulating the myoCF marker ACTA2, SB431542 specifically downregulated the profibrotic-related genes SMYD3, and RASGRF1 (Supplementary Fig. 17c). Taken together, these findings demonstrated that the prominent functional repair of cryoinjured hEHT after combination treatment was jointly achieved by the enhancement of cellular stress resistance by Y27632, the reduction of CM apoptosis and promotion of CM proliferation by CHIR99021, and the direct antifibrotic effect of SB431542.

MI mice exhibited cardiac functional recovery to Y27632, CHIR99021, and SB431542 to treatment in combination

Undeniably, immature and proliferating CM subpopulations in our hEHT injury repair model can be essential for initiating regenerative repair after injury, as demonstrated in the cryoinjury model of neonatal mice16. The heart of neonatal mice with 15% direct apical excision can fully recover within 21 days, demonstrating its powerful regenerative capacity, but this capacity declines sharply with age75. Considering that our model of myocardial injury repair focused more on fibrotic remodeling and screening for related therapeutic targets, we, therefore, performed transmural cryoinjury (penetrating the entire ventricular wall) in neonatal mice at 3 days postnatal age (P3) to promote cardiac healing with fibrotic scarring. Post-MI, the myocardial pathological remodeling process is multi-factor led and highly dynamic in vivo, which includes the early inflammatory phase, cardiac replacement fibrosis phase, and scar maturation phase3. Similarly, we validated the effects of Y27632, CHIR99021, and SB431542, these single-factor treatments, and their phased combination treatments on myocardial injury repair in the above cryoinjury model of neonatal mice (Supplementary Fig. 18a). After 12 days of treatment, the heart in the vehicle groups showed thinning of the ventricular wall and fibrotic scar filling (Supplementary Fig. 18b), whereas only the combination treatment can preserve ventricular structure and significantly reduce the fibrotic area (Supplementary Fig. 18c).

Subsequently, we developed the MI model in adult mice and evaluated the therapeutic effects of Y27632, CHIR99021, SB431542, and their combination (Fig. 8a). Echocardiography assessment (Fig. 8b) revealed that both the ejection fraction (EF) and fractional shortening (FS) significantly declined in all treated groups compared with the sham-operated group at day 1 post-MI. However, only the combined treatment enhanced cardiac function considerably after 21 days post-treatment compared to the vehicle group (Fig. 8c, d). The Masson staining analysis (Fig. 8e) further indicated that the combined treatment can significantly reduce the fibrotic area compared to the vehicle group (Fig. 8f). Notably, the phased single-factor treatment with CHIR99021 in days 7-14 (cardiac replacement fibrosis phase) post-MI also significantly reduced the formation of fibrotic scar (Fig. 8f) but failed to rescue the cardiac function (Fig. 8c, d). In contrast, sustained CHIR99021 treatment throughout the remodeling process (21 days post-MI) in adult MI mice (Supplementary Fig. 19a) failed to reduce the fibrotic area. Phased interventions with Y27632, CHIR99021, and SB431542 still facilitated functional recovery post-MI (Supplementary Fig. 19b–f), indicating the importance of symptomatic treatment of remodeling stages with different pathological features. The above results further validate that the potential value of the Y27632, CHIR99021, and SB431542 identified from the hEHT injury repair model, their phased combination can distinctively have a positive impact on myocardial pathological remodeling.Fig. 8 The combination treatment reduced the fibrotic area and enhanced cardiac function in the adult mouse model of MI.

a Schematic of various treatments (DMSO, Y27632, CHIR99021, SB431542, and their combination) to adult mice post-MI. b Representative images of M-code echocardiography from Sham, Vehicle, Y27632, CHIR99021, SB431542, and their combination-treated mice after 21 days of treatment. c Ejection fraction measured by echocardiography in different groups of mice before treatment and 21 days after treatment. n = 7 mice for Sham, Vehicle and Combination; n = 6 mice for Y27632 and CHIR99021; n = 5 mice for SB431542. d Fraction shortening measured by echocardiography in different groups of mice before treatment and 21 days after treatment. n = 7 mice for Sham, Vehicle and Combination; n = 6 mice for Y27632 and CHIR99021; n = 5 mice for SB431542. e Representative Masson staining images of heart sections from various groups at 21 days after treatment. Scale bar,2.5 mm. f Quantitative analysis of the fibrotic area measured from Masson staining image from different group mice at 21 days after treatment. n = 7 mice for Vehicle and Combination; n = 6 for Y27632 and CHIR99021; n = 5 mice for SB431542. Data are presented as mean ± SEM in (c), (d), and (f). p values were calculated by Dunnett’s multiple comparisons test vs. vehicle at the same time point in (c), (d), and (f).

To further assess the impact of different treatments on the electrophysiological recovery of MI mice hearts, we analyzed the calcium activity in treated ventricles under four loading conditions using optical mapping (Supplementary Fig. 20a). In the control ventricle, as we found in the hEHT injury repair model, the area of disturbed calcium signaling progressively increased with increasing electrical pacing frequency and ISO loading (Supplementary Fig. 20b). In addition, we observed reduced calcium signaling amplitude and prolonged CSD80 in disturbed area, along with the occurrence of arrhythmias at high-frequency pacing (Supplementary Fig. 20c, d). The combination treatments significantly decreased abnormal functional areas (Supplementary Fig. 20b) and restored ventricular conduction velocity and conduction direction homogeneity to normal levels (Supplementary Fig. 20e). Based on the integrated scoring system developed to evaluate all characteristic parameters related to the calcium signaling activity, the combination treatment demonstrated the best effect in rescuing the electrophysiological dysfunction in the adult infarcted mice (Supplementary Fig. 20f).

Discussion

Current studies based on animal MI models76 and human pluripotent stem cell-derived CF8 have provided valuable insights into the onset and progression of myocardial pathological remodeling. However, challenges like species differences and low drug screening throughput persist77. Developing the hEHT model that mimics myocardial pathological remodeling for screening therapeutic targets that could normalize myocardial physiology following injury is crucial. Our hEHT repair model mimicked the phased remodeling process, including cellular stress, CF activation, and ECM deposition post-injury. The remodeled area was characterized by fewer CM, increased CF, and more type I collagen secretion and fibronectin. Our model also faithfully reproduced the electrophysiological dysfunction caused by fibrotic scar, represented by the abnormalities in calcium signaling activity in the remodeled area.

The evolution and transformation of CF act as the major events in driving the development of myocardial remodeling. Prior studies relied on animal MI models78 or clinical samples79. Clues on how human CF transits from a quiescent state to an active state and their role in fibrotic scarring are limited in animal models, and at the same time, clinical samples cannot encompass the pathological progression from healthy to scarred myocardium. In our hEHT repair model, transcriptomic analysis identified CF subpopulations in hEHT resembling both healthy and infarct myocardium: epithelial-like CF (CD44+, UPK3B+, LUM+), transition-state CF (CD44+), quiescent CF (HTRA3+, TCF21+), myoCF (ACTA2+) and proliferating CF (MKI67+). In cryoinjured hEHT, CF4 displayed notable cell migration and specification in the early remodeling period compared to control hEHT. myoCF showed enhanced proliferation and collagen assembly activity in the late period. These findings indicated that the CF might undergo the early stress response and late activation during myocardial remodeling, partly mimicking the post-MI phenotype in vivo. TGFβ signaling was upregulated in all CF subpopulations, while ROCK/Rho, MAPK/ERK, PI3K/AKT, WNT, NFκB, cAMP, and bFGF regulate myocardial fibrosis in various CF and CM subpopulations. Interestingly, previous studies noted myoCF conversion and epithelial-mesenchymal transition in fibrotic myocardium80. Our annotation of CF subpopulations further supported these observations, emphasizing the need for further investigation into these identities’ transitions, and our model can facilitate the exploration of the markers of CF activation.

Our mini hEHT injury repair model allows rapid testing of modulators identified from transcriptome analysis. Y27632, CHIR99021, and SB431542 were identified to show anti-fibroblast activation and pro-cardiomyocyte in situ refilling. The ROCK inhibitor Y27632 was reported to improve cardiac function81 and also reduce apoptosis of transplanted CM82 in MI mice. In the hEHT injury repair model, the ROCK/RhoA signaling-related TF BHLHE40 was upregulated in CM (Supplementary Fig. 8b) and correlated with MI-induced inflammatory response83. CHIR99021 enhanced hPSC-CM proliferation84, evidenced by ETS1 upregulation in immature CM1 at the late remodeling period (Supplementary Fig. 8b), while ETS1 can directly promote cardiac development through WNT signaling85. Meanwhile, SB431542 inhibits the TGF-β receptor and reduces CF activation-related gene expression86. This contrasts with TGFβ signaling upregulation by myoCF in cryoinjured hEHT (Fig. 3k). In addition, myoCF also directly interacted with CM through TGFβ1(Supplementary Fig. 12c), potentially inducing CM stress87. These evidences further support the potential anti-apoptotic, pro-cardiomyocyte proliferation, and anti-fibroblast activation effects of Y27632/CHIR99021/SB431542.

The myocardial pathological remodeling encompasses stress response, CF activation, and scar maturation post-MI. Ongoing fibrosis risks functional impairment, but phased intervention with different modulators can be more conducive in guiding the early fibrotic response to participate in myocardial defect repair while arresting persistent and excessive fibrosis. Notably, the phased combination of Y27632, CHIR99021, and SB431542 effectively reduced dysfunction area and improved calcium activity. Our studies in MI mice demonstrated better functional recovery with phased combination treatment targeting over single-factor treatments. Although the effect of other combinations of phased interventions and the regulatory mechanisms behind them are yet to be verified, this phased intervention strategy undoubtedly provided valuable insights for developing therapeutic regimens against myocardial injury.

Undeniably, the absence of immune cells and the immaturity of hPSC-CM in hEHT remains a noticeable challenge for our hEHT repair model to comprehensively mimic the myocardial pathological remodeling post-MI in adult hearts. Nonetheless, the occurrence of immune system-related terms from transcriptomic analysis still gave confidence for this engineered model to explore how immune cells respond to regional stress and regulate subsequent fibrosis mediated by CF with various identities. In summary, we have developed an engineered model of myocardial injury-repair simulating the phased pathological remodeling and functional impairment post-MI, based on which we can deeply analyze the cell fate regulation and subcellular transformation during myocardial remodeling. More importantly, this model provides a humanized screening platform for screening therapies targeting myocardial injury, promoting better recovery of fibrotic myocardium.

Methods

hPSC culture and cardiomyocyte differentiation

Human iPSC line WTC88 (Coriell Institure, GM25256) and Human ESC line H989,90 (WiCell, WB68075) were used and seeded on Matrigel (Corning, 354277) coated plate at the cell density of 0.02 million/cm2. The hPSC was maintained in mTeSR1 (STEMCELL Technologies, 85850) supplemented with 10 μM Y27632 (STEMCELL Technologies, 72302) on the first day and passaged every 5 days using Versene Solution (Thermo Fisher, 15040066). For inducing hPSC differentiated into CM, the mTeSR1 was changed into RPMI-1640 (Thermo Fisher, C11875500BT) supplemented with 0.2 mg/mL L-Ascorbic acid-2-phosphate sesquimagnesium salt hydrate (Sigma-Aldrich, A8960), B-27 supplement minus insulin (Shanghai BasalMedia, X064C5), and 5-8 μM CHIR99021 (STEMCELL Technologies, 72054) when the hPSC reached 80-90% confluence. After 48 hours, the medium was changed into the 1640/B27(-INS) medium. On day 3 of differentiation, 5 μM IWR1 (STEMCELL Technologies, 72564) was introduced into the 1640/B27(-INS) medium for another 48 hours. After that, the 1640/B27(-INS) medium was changed every 2 days. On day 9, beating CM can be observed. The differentiated cells on days 14-16 were dissociated into single cells using 2 mg/mL collagenase I (Sigma-Aldrich, C0130) for 1 hour and 0.25% trypsin/EDTA (Thermo Fisher, 25200056) for 5 minutes at 37 °C. After digestion termination using stop buffer (high glucose DMEM (Thermo Fisher, C11995500BT), supplemented with 50% fetal bovine serum (FBS) and 20 μg/mL DNase I (Millipore, 260913)), the harvested cells were used for fabricating hEHT.

hEHT fabrication and culture

Similar to the method as previously described in Refs. 10,11, the 9 × 9 mm polydimethylsiloxane (PDMS, Dow Corning) square molds were treated with 0.2% Pluronic F127 (Sigma-Aldrich, P2443) for at least 1 hour and washed by DPBS for the next step. After dissociation, 1.0 × 106 differentiated cells were added into 58 μL 1× cardiac medium consisting of low glucose DMEM (Thermo Fisher, 10567014), 2 μg/mL Vitamins B12 (Sigma-Aldrich, V2876), 2 mg/mL 6-Aminocaproic acid (Sigma-Aldrich, A2504), 1% Penicillin-Streptomycin (Thermo Fisher, 15140122), 10% FBS and 2.4 μL 50 U/mL thrombin (Sigma-Aldrich, T7201). Then the cardiac medium was mixed with the hydrogel solution consisting of 24 μL 2× cardiac medium, 24 μL 10 mg/mL fibrinogen (Sigma-Aldrich, F4883), and 12 μL Matrigel (Corning, 354277). The 120 μL cell-laden hydrogel was transferred to the 9 × 9 mm Nylon frames in the PDMS model and placed into the 37 °C incubator. After 30 min for polymerizing, the hEHT was transferred into the 24-well plate on a rocking platform and cultured in the hEHT medium consisting of RPMI 1640, B-27 supplement minus insulin (Shanghai BasalMedia, X064C5), 0.2 mg/mL ascorbic acid (Sigma-Aldrich, A8960), 2 mg/mL 6-Aminocaproic acid (Sigma-Aldrich, A2504), 1 mM sodium pyruvate (Thermo Fisher, 11360070), 0.1 mM non-essential amino acid (Thermo Fisher, 11140050), 0.45 μM 1-thioglycerol (Sigma-Aldrich, M6145), 5% FBS and 1% Penicillin-Streptomycin (Thermo Fisher, 15140122). 10 μM Y27632 (STEMCELL Technologies, 72302) were added into the hEHT medium for the first 24 hours. The hEHT medium was changed every 2 days.

Development and assessment of the hEHT injury repair model

After 4 days of cultivation, we designed and 3D-printed the cryoinjury device with a conical tip of 0.35 mm diameter and 8 mm height using LCD based SLA 3D Printer (Anycubic, Photon) to introduce standardized cryoinjury into hEHTs. After pre-cooling with liquid nitrogen for 15 seconds, the cryoinjury device easily penetrates and cryoinjury the hEHT with four physical holes of approximately 300–500 μm in diameter. For developing the mini hEHT injury repair model, the mini hEHT fabrication device (Fig. 5a) and cryoinjury pedestal (Fig. 5b) were designed by SolidWorks. The design files were exported to STL. Format and 3D printed by WeNext Technology Co., Ltd using nylon. The mini hEHTs were fabricated using the same method for fabricating hEHT and then batch cryoinjured by the 0.3 mm diameter stainless steel needle fixed in the 3D printed pedestal after 3 days of culture. The cryoinjured hEHTs or mini hEHTs were cultured in the hEHT medium for another 6 days for remodeling. The following compounds were added into the hEHT medium to intervene in the entire remodeling process of the cryoinjured hEHT: 25 ng/mL bFGF (MedChemExpress, HY-P7004), 10 μM Y27632 (STEMCELL Technologies, 72302), 10 ng/mL Rho activator II (Cytoskeleton, CN03-A), 5 μM CHIR99021 (STEMCELL Technologies, 72054), 5 μM IWR1 (STEMCELL Technologies, 72564), 10 ng/mL TGFβ1 (PeproTech 100-21-10UG), 5 μM SB431542 (STEMCELL Technologies, 72232), 5 μM Forskolin (MedChemExpress, HY-15371), 5 μM SQ22536 (MedChemExpress, HY-100396), 3 μM 740YP (MedChemExpress, HY-P0175), 5 μM LY294002 (MedChemExpress, HY-10108), 5 μM DMU212 (MedChemExpress, HY-137977), 3 μM SCH772984 (MedChemExpress, HY-50846), 5 ng/mL PMA (MedChemExpress, HY-18739), 5 μM PDTC (MedChemExpress, HY-18738), 5 μM Prostaglandin E2 (MedChemExpress, HY-101952), 5 μM NS398 (MedChemExpress HY-13913). The 10 μM Y27632 was added to the hEHT medium for combination treatment in the first 2 days. After 2 days, the Y27632 was removed, and the CHIR99021 was added for another 2 days. In the final 2 days, only the SB431542 was added to the hEHT medium. The 0.1% DMSO was added to the hEHT medium as the control, and all the medium was changed every 2 days.

pLV-mCherry and TroponinT-GCaMP5-Zeo lentivirus production

The pLV-mCherry (Addgene, 36084) and TroponinT (TNNT2)-GCaMP5-Zeo (Addgene, 46027) were packaged by co-transfection with the lentiviral packaging plasmid psPAX2 (Addgene, 12260), and the VSV-G envelope expressing plasmid pMD2.G (Addgene, 12259) in 293 T cells using Hieff Trans Liposomal Transfection Reagent (Yeasen, 40802ES03). After 48 hours, the culture supernatants were filtered using 0.22 μm filters (Millipore, SLGP033RB) and centrifuged using Amicon® Ultra-15 Centrifugal Filter Unit (Millipore, UFC910024) for harvesting lentivirus in Hanks’ solution (Sangon, B548148).

Time-lapse imaging of the remodeling of cryoinjured hEHT

For labeling the non-CM populations in the differentiated cells, the formulation of the 120 μL cell-laden hydrogel was changed into 1.0 × 106 differentiated cells, 28 μL pLV-mCherry lentivirus, 28 μL TNNT2-GCaMP5 lentivirus, 2.4 μL 50 U/mL thrombin and the 60 μL hydrogel solution. After culture for 4 days, the labeled hEHT was cryoinjured and cultured for another 2 days to go through the stress period. Then, the cryoinjured hEHT was transferred to a 3.5 cm confocal dish with the hEHT medium. For the prolonged recording of the movement trajectory of the GFP-labeled CM and the mCherry-labeled but not GFP-labeled CF during the scar-forming process of cryoinjured hEHT, the 3.5 cm confocal dish was placed in the Heating Insert P Lab-Tek™ S compact (PECON) with the CO2-Cover HP (PECON) for providing stable culture temperature and CO2 concentration using CO2 control device (Zeiss, CO2 Module S) and temperature control unit (Zeiss, TempModule S). The whole device was assembled into the confocal system (Zeiss LSM980). The GFP/mCherry/phase-contrast images of the scar-forming region were taken every 30 minutes until the scar-forming was complete.

Immunofluorescence staining

The cells cultured in 3.5 cm confocal dishes or the hEHTs were fixed with 4% PFA for 30 minutes. After washing twice with DPBS, the samples were blocked and permeabilized in DPBS supplemented with 0.2% Triton X-100 and 5% donkey serum at 4 °C overnight. The following primary antibodies were used in this study: Vimentin (Abcam, 92547, 1:200), Cardiac Troponin T (Abcam, ab45932, 1:200), Cardiac Troponin I (Abcam, ab56357, 1:100), Transgelin (Abcam, ab10135, 1:200), Collagen I (Invitrogen, MA1-26771, 1:100), Fibronectin (Abcam, ab2413, 1:100), Sarcomeric α-actinin (Sigma-Aldrich, A7811, 1:200), Alpha smooth muscle actin (Abcam, ab7817, 1:200), Tie-1 (Proteintech, 19329-1-AP, 1:100), WT1 (ABclonal, A17006, 1:200), Fibroblasts antibody TE7 (Sigma-Aldrich, CBL271, 1:200), CD44 (Cell Signaling Technology, #3570, 1:200), CXADR (Invitrogen, MA5-29208, 1:100), MYH (Abcam, ab207926, 1:200). The samples were incubated with these primary antibodies at 4 °C overnight, followed by the species-appropriate AlexaFluor (Invitrogen) secondary antibodies (1:400 dilution) for 2 hours at room temperature. Dyes such as Cell-ROX (Thermo Fisher, C10422), Hoechst (Thermo Fisher, H21492), and TdT-mediated dUTP Nick End Labeling (TUNEL) apoptosis detection kit (Yeasen, 40307ES50) were also used according to manufacturer’s instructions in this study. After washing twice with DPBS, the confocal images were taken by Zeiss LSM980 and processed using ImageJ. For calculating the percentage of CM volume (Pcm) in the remodeled area of cryoinjured hEHT (Supplementary Fig. 14b), the calculation formula is1 Pcm=Areac−Area1+⋯+Areac−Arean−1+Areac−Arean×Zn/(n−1)Areac×Zn

Optical mapping of hEHT

The calcium activity of remodeled hEHT was recorded as the established method91. Briefly, the hEHT were incubated with 2.5 μM Rhod2 at 37 °C for 20 minutes in the hEHT medium. After washing twice with DPBS, 5 μM blebbistatin (Sigma-Aldrich. B0560) was added into the hEHT medium to eliminate motion artifacts deriving from CM’s contractions during recordings. The remodeled hEHTs under different treatments were stimulated (8–10 V) by a bipolar platinum point-electrode at 1 Hz, and 1 or 1.5 Hz with 1 μM isoproterenol (Sigma-Aldrich, I0599990) supplemented in the hEHT medium. The high-speed imaging system (SciMedia, MiCAM02) with the 530 nm LED illumination system (SciMedia, LEX2-LE4-G) was applied to acquire 2048 frames of calcium activity images over 10 seconds for each recording.

Apical cryoinjury model in neonatal mice

This protocol was performed as previously described16 and approved by the Hubei University Animal Ethics and Welfare Committee (20240066). Mice were housed in a pathogen-free room with a 12-hour light/12-hour dark cycle, a temperature of 24 °C ± 2 °C, and a relative humidity of 40-70%. Briefly, the neonatal mice at 3 days of postnatal (P3) were placed on ice for 3–4 minutes. Once anesthetized, they were immediately transferred to the precooled operating table and taped down to secure the body. The left thoracotomy was performed for exposure of the heart between the 3rd and 4th intercostal space. A 1-mm diameter copper probe precooled in liquid nitrogen was applied to the left ventricle near the apex for 8-12 seconds to induce transmural cryoinjury. The chest wall and skin were progressively closed with 7-0 polypropylene sutures. After surgery, mice were placed on the 37°C-heating pad for recovery and randomly divided into five groups. Y27632, CHIR99021, and SB431542 were dissolved in DMSO at 5 mg of the small molecule per 1 kg body weight (5 mg/kg) and injected subcutaneously into mice after diluting in corn oil. For combination treatment, Y27632, CHIR99021, and SB431542 were injected subcutaneously on days 1, 5, and 9 after cryoinjury. For single-factor treatment, only a small molecule was injected subcutaneously once on day 1, day 5, or day 9 after cryoinjury, and DMSO was injected at the remaining time points. The vehicle group used Equal amounts of DMSO at all three injection times. Mice were sacrificed after 12 days of treatment, and their hearts were excised for further histological analysis (n = 9 mice for the vehicle; n = 7 mice for Y27632; n = 6 for CHIR99021 and SB431542; n = 9 mice for combination).

Mouse myocardial infarction model

Animal protocols were approved by the Hubei University Animal Ethics and Welfare Committee (20220053), and animal experiments were performed based on them. All procedures involving animals were performed according to the NIH guidelines. A mouse myocardial infarction model was performed as previously described92. Adult 8–9-week-old male C57/BL6 mice were anesthetized by intraperitoneal administration of tribromoethanol (400 mg/kg), intubated, and mechanically ventilated with a rodent respirator. The left anterior descending (LAD) coronary artery was permanently occluded using a 7-0 polypropylene suture. The chest was closed sequentially suturing rib and skin with a 5-0 suture. For non-infarcted controls, mice underwent the sham operation where the ligature around the left anterior descending coronary artery was not tied. Mice recovered from anesthesia under warm conditions with normal ventilation. One day after the MI model, the cardiac function was evaluated by echocardiography with the VINNO V6 Vet system. Infarcted mice were averagely divided into five groups: Vehicle (DMSO), Y27632, CHIR99021, SB431542, Y27632 + CHIR99021 + SB431542 (Combination) group, according to echo data with the comparable LVEF and LVFS. There were two types of drug administration methods for MI mice: 1) Sustained single-factor treatment: 3 mg/kg Y27632, 3 mg/kg CHIR99021, or 3 mg/kg SB431542 dissolved in DMSO were injected intraperitoneally every other day for three weeks in each single drug group. 2) Phased single-factor treatment, 5 mg/kg Y27632, or 5 mg/kg CHIR99021, or 5 mg/kg SB431542 were intraperitoneally injected once on day 0, day 7, or day 14 post-MI, and DMSO was injected at the remaining time points. The vehicle group used equal amounts of DMSO at all three injection times. For the combination treatment, these drugs were intraperitoneally injected one drug per week (Y27632 for the first week, CHIR99021 for the second week, and SB431542 for the third week). The vehicle group was treated with equivalent DMSO. After three weeks, the cardiac function of survival animals was re-evaluated by echocardiography, then animals were sacrificed, and hearts were excised for other analyses.

Histological analysis

The harvested hearts were fixed in 4% paraformaldehyde for 24-36 hours at 4 °C, halved 1-2 mm above the ligature knot, dehydrated in an ethanol and xylene series, and embedded in paraffin. For the MI mouse model, hearts were continuously sectioned at 5 μm thickness from the ligation site to the apex at an interval of 300 μm between each section group. For the cryoinjured mice, hearts were serially sectioned at 6 μm thickness from the cryoinjury site to the apex with a 150 μm interval between each section group. Three section groups were collected from each heart. Masson’s trichrome was performed using standard procedures92. Fibrotic area was calculated as the average percentage of collagen fiber area in each of the three left ventricular sections to the total area of the left ventricular wall. The percentage of the collagen fiber area was identified and calculated using the machine learning-based tool FibroSoft93 and Image J software.

Optical mapping in rats and mice with myocardial infarction

All the rat animal experiments were performed in Henan Scope Research Institute of electrophysiology under the experimental animal usage guidelines of Henan Provincial Experimental Animal Center and were approved by the Animal Ethics Committee of Scope Research Institute of electrophysiology (SGll220821044). Similar to the methods described before94, the 6–8-week-old male SD rats were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China). The adult male rats weighing 200-250 g were anesthetized with isoflurane (RWD, R510-22-10) and fixed in a supine position on the operating table. The small animal ventilator (ZSLAB, ZS-MV-HX) was used for maintaining their breathing, and the electrocardiogram leads (TECHMAN, BL-420N) were connected to monitor the rat’s electrocardiogram in real-time. After depilation and disinfection of the precordial area, a 2 cm incision was made at the second and third ribs of the sternum. The skin and muscle tissue were bluntly separated to expose the heart. The left anterior descending branch under the left auricle and pulmonary artery cone was ligated with a 5-0 nylon thread to cause acute ischemia. ST-segment elevation in the electrocardiogram represents successful ligation. The intercostal space, muscle, and skin were sutured sequentially, and the skin was disinfected with iodophor and sutured. After 4 weeks of feeding, the rats were anesthetized and euthanized to remove the heart. The heart was placed on the Langendorff perfusion apparatus (Scope, SG-LP011) and the aorta was retrogradely perfused with K-H solution containing 119 mM NaCl, 4 mM KCl, 1.8 mM CaCl2-2H2O, 1 mM MgCl2-6H2O, 1.2 mM KH2PO4, 25 mM NaHCO3 and 10 mM glucose at 37 °C and 10 mL/min flow rate. After 15 minutes of stabilization, 1 mg/mL blebbistatin (Abcam, ab120425) was perfused into the heart to eliminate motion artifacts. Intracellular calcium changes were measured using 1 mg/mL RHOD-2AM (Abcam, ab142780). The entire heart was illuminated with 549 nm excitation light (MappingLab, LEDC-2001), and CMOS cameras (MappingLab, OMS-PCIE-2002) were used to capture the fluorescent signal emitted by the heart. The intracellular calcium signal under 5 Hz stimulation (stimulation at the apex of the heart with twice the threshold current) was recorded. For optical mapping in the heart of drug-treated MI mice, the main difference compared to infarcted rats was that the perfusion flow rate was reduced to 2.5 mL/min, and calcium signaling activity was recorded under four loading conditions (8 or 20 Hz electrical pacing with or without 1 μM isoproterenol).

Processing of data from optical mapping

The commercially available analysis software OMapScope 4.0 (MappingLab, Version 5.7.8) and BV-Ana Analyzer (BrainVision, Version 16.04.20) were applied for processing the optical mapping data from rat MI hearts and cryoinjured hEHTs. Gaussian spatial filtering (3 × 3 pixels) and median filtering (3 × 3 pixels) were used for the spatial alignment and processing of the calcium signal.

As shown in Fig. 2f, after normalizing using the background fluorescence(F/Fb), the maximum upstroke time or recovery time was determined as the time corresponding to the maximum rate of rise of the calcium signal depolarization or the maximum rate of decline of the calcium signal repolarization. The maximum depolarization slope or maximum repolarization slope was then defined as the maximum upstroke rate or maximum recovery rate. Calcium signal amplitude, and duration at 50% (CSD50) or 80% (CSD80) repolarization were also calculated. The maximum upstroke time was regarded as the excitation time of each pixel, and the spatial time arrays of a total of 20 × 20 pixels from the uninjured area or remodeled area in rat MI hearts and cryoinjured hEHTs were extracted as single ROI and further analyzed in the software Arrow Map Tool (Mapping Lab, Version 1.3) to evaluated conduction velocity (CV). The coefficient of variation of all CV in the 20 × 20-pixel matrix was calculated to evaluate the velocity value homogeneity. To evaluate the conduction direction homogeneity, first, calculate the average vector of the propagation direction of 400 pixels. Then, calculate the cosine similarity between the propagation direction of each of the 400 points and the average vector of the propagation direction in turn. Finally, take the average of the cosine similarity (cosθ) to evaluate whether the propagation direction is consistent or not (homogeneity level). The closer the average cosθ is to 1, the more consistent the propagation direction of all pixels in ROI. The closer the average cosθ is to 0 or even −1, the more inconsistent the direction. For developing the integrative scoring system, the average value of the calcium activity characteristics parameters in the uninjured areas of the control group was regarded as the criterion to rank the effeteness (average value of the corresponding parameter) of different treatments on functional recovery.

Bulk RNA sequencing

The hEHT and corresponding controls were collected on days 2 and 4 after cryoinjury and their total RNA was extracted using the RNeasy Fibrous Tissue Mini Kit (Qiagen 74704) according to the manufacturer’s instructions. Each group had 3 biological replicates. The cDNA libraries were constructed using KAPA Hyper Prep Kits (Roche KK8504) and sequenced on the Illumina Novaseq platform using the double-end sequencing (Paired-End) PE150 method. For bulkRNA-seq targeting CM and CF in treated hEHT (10 μM Y27632 on days 0–2 after cryoinjury, 5 μM CHIR99021 on days 2-4, 5 μM SB431542 on days 4-6) and corresponding control hEHT, these hEHTs were dissociated with 2 mg/ml collagenase type II and IV at 37 °C for 1 hour, followed by two washes with high-glucose DMEM. Cell clusters were further digested with 0.25% trypsin-EDTA at 37 °C for 4 minutes. After collecting cell precipitates by centrifugation at 300 × g for 5 minutes, these precipitates were resuspended in hEHT medium and cultured in uncoated cell culture plates. After 1 hour, unattached cells (CM) and attached cells (CF) in the plate were collected separately using TRIZOL for further cDNA library construction and sequencing. Raw reads were trimmed adapter sequences and removed low-quality reads by cutadapt (v1.10), and mapped to the GRCh37/hg19 reference genome by tophat2 (v2.0.13). After removing obvious outliers in each group via PCA analysis, the differentially expressed genes with log2|fold-change | ≥ 1 and P < 0.01 between cryoinjured hEHT and control hEHT were selected for Gene Ontology Biological Processes and KEGG pathway analysis via The Database for Annotation, Visualization and Integrated Discovery (DAVID) (https://david.ncifcrf.gov/).

Single-cell RNA sequencing

The cryoinjured hEHTs under the early and late period of the remodeling process were dissociated by 2 mg/mL collagenase II (Sigma-Aldrich, C6885), and 2 mg/mL collagenase IV (Sigma-Aldrich, C5138) for 1 hour. After collagenases were removed, the dispersed hEHTs were further digested into single cells with 0.25% trypsin-EDTA at 37°C. Fluorescence-activated cell sorting was applied to obtain a single cell suspension, with a high percentage of live cells above 80%. Single-cell RNA-seq libraries were prepared according to the manufacturer’s instructions (Chromium Single Cell 3’ Reagent Kits User Guide (v3.1 Chemistry Dual Index)). Briefly, cells at a limiting dilution, barcoded single-cell gel beads, and partitioning oil were combined onto chromium next GEM chip to generate Gel Beads-in-emulsion (GEMs). Then, the gel beads were dissolved and mixed with a master mix containing reverse transcription reagents. Followed by demulsification, cDNA library construction was performed accordingly. All libraries prepared for this study were sequenced on NovaSeq 6000. Three biological replicates in each treatment condition were dissociated and split into 4 fractions to be sequenced in equal parts. The qualitative analysis of the sequenced data was performed first. The Phred quality score (Q) was defined as a property logarithmically related to the base-calling error probabilities (P) to measure the quality of each read base during the sequencing process. The formular was: Q = −10 log10P. The sequencing quality scores are shown in Supplementary Table 1.

scRNA-seq data processing

Data were generated and aggregated to the human genome (GRCh37, ftp://ftp.ensembl.org/pub/grch37/release-84/gtf/homo_sapiens/Homo_sapiens.GRCh37.82.gtf) by CellRanger software (10x Genomics) and raw data were further processed using the Seurat package in R95. 35230 high-quality cells were extracted to identify distinct cell populations and subsequent downstream analyses. The following standards were adopted to perform the quality control process: (1) genes expressed by less than 3 cells were excluded; (2) cells that expressed fewer than 400 genes or the total number of molecules detected within a cell fewer than 1,000 were removed because it may be a dead or an empty droplet; (3) cells that expressed over 9,000 genes or the total number of molecules detected within a cell more than 10,000 were also excluded because it indicated that the “cell” could be a doublet or multiplet; (4) cells with more than a quarter of unique molecular identifiers (UMIs) were derived from the mitochondrial genome were not considered as well. The data were normalized using the “NormalizeData” function and further scaled using the “ScaleData” function of the Seurat package. To perform the linear dimensional reduction of this dataset, we first detected 2,000 highly variable genes using the “vst” method of the Seurat FindVariableGenes function, and then the selected genes were summarized by principal component analysis (PCA).

Identification of cell types and differentially expressed genes

The two-dimensional uniform manifold approximation and projection (UMAP) was calculated using the “RunUMAP” function and Graph-based clustering was conducted on cluster cells according to their gene expression profile using the “FindClusters” function of the Seurat package. Cell clusters in the resulting two-dimensional UMAP were annotated to known cell types based on previously reported marker genes33, including DLK1, COL1A2, PDGFRA, GSN, LUM, COL1A1, DCN for CF, TBX18, WT1, ALDH1A2, UPK3B for epicardial cell, ERG, SOX7, COL4A1, GNG11, TIE1, CDH5, EMCN, RAMP2 for endothelial cell, and MYH6, PLN, MYL7, TTN, ENO3, NIK2-5, ACTN2, TNNC1, TNNT2 for CM. Additionally, we used the SingleR package96 to automatically annotate the cell types. Cells expressing two or more markers simultaneously were removed. Second-level clustering was applied to both CM and CF, using 20 dimensions for clustering. A clustering resolution of 0.22 was used for CF, while a resolution of 0.5 was applied for CM. UMAP was utilized to visualize the result.

Differentially expressed gene analysis

Differentially expressed genes (DEG) of different cell clusters, as well as those of different samples, were identified using the “FindMarkers” function of the Seurat package. DEGs were selected only if the gene had an average log fold change 0.4 higher than the average expression in the other clusters and the adjusted p-value less than 0.05. Heatmaps were performed to show the DEGs of different cell clusters.

Transcription factors (TFs) analysis

For constructing gene regulatory networks, we used the pySCENIC package (version 0.9.1) with default parameters97. Pre-processed, normalized data from Seurat were used to identify enriched TFs in different cell types from different groups. The GRNboost2 algorithm was used to infer gene-gene co-expression relationships between TFs and their potential targets. The regulon prediction step was performed using the databases from https://resources.aertslab.org/cistarget. Each regulon contained a TF and its target genes enriched for the TF’s motifs. The AUCell algorithm assessed the activity scores of each regulon within single cells.

Pseudotime trajectory inference

The Monocle R package (version 2.30.0) was used for the developmental trajectory inference98. The analysis began by separating the cell clusters of interest using the “subset” command in Seurat. A CellDataSet object was then created using the “newCellDataSet” function in Monocle. After calculating size factors and estimating dispersions, genes were selected for pseudotime definition in a semi-supervised manner. Specifically, genes were filtered based on mean expression level and variability across cells, using the following criteria: mean expression >= 0.5 and dispersion empirical >= 1.25 * dispersion fit. Dimension reduction was performed using the “reduceDimension” function with the “DDRTree” method. Cells were ordered in pseudotime, and visualization was performed using the “plot cell trajectory” plot genes in “pseudotime” and “plot genes branched heatmap” functions.

Cell–cell interaction analysis

CellPhoneDB (version 5.0) was applied to study cell-cell interactions in different cell types from different groups99. Pre-processed and normalized single-cell RNA sequencing data from Seurat were used as input. We used the latest ligand-receptor interaction database from CellPhoneDB (GitHub—ventolab/cellphonedb-data) to evaluate cellular interaction networks. Interactions were visualized using the kplots package.

Statistics and reproducibility

Each experiment contained at least 3 biological replicates or as indicated in the figure legends. GraphPad Prism 9 was used for statistical analysis. All data were reported as means± standard error of the mean (SEM). Experiments involving two groups were analyzed using unpaired two-tailed Student’s t-test. Sidak’s, Tukey’s, or Dunnett’s multiple comparisons were otherwise assessed by ANOVA and indicated in the corresponding Figure legend. p value less than 0.05 was considered statistically significant.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Supplementary information

Supplementary Information

Peer Review File

Description of Additional Supplementary Files

Supplementary Movie 1

Supplementary Movie 2

Supplementary Movie 3

Supplementary Movie 4

Supplementary Movie 5

Supplementary Movie 6

Supplementary Movie 7

Supplementary Movie 8

Reporting Summary

Source data

Source Data

Supplementary information

The online version contains supplementary material available at 10.1038/s41467-024-52221-9.

Acknowledgements

H.Z. was funded by the National Key R&D Program of China (2019YFA0110401). D.Z. was funded by the National Key R&D Program of China (2021YFA1101902, 2018YFA0109100) and the National Natural Science Foundation of China (32171107). We also thank Yan Qi and Shutao Xia from Hubei University, and William T. Pu from Boston Children’s Hospital for reviewing the manuscript.

Author contributions

P.Y. and L.Z. contributed equally to this study. L.C., D.Z., and H.Z. conceptualized the study. P.Y., L.Z., J.G., L.C., and D.Z. designed the experiments; P.Y., L.Z., S.W., and J.G. performed experimental studies in hPSC culture, model establishment, immunostaining, and optical mapping. L.C., P.Y., S.W., and Z.L. performed the analysis of the therapeutic efficacy of different compounds in MI mice. L.Z., H.C., W.S., and Y.Z. designed and assisted in single-cell RNA sequencing analysis. G.W. guided the calcium activities study in myocardial infarction rats and mice. P.Y., L.Z., S.W, J.N.S., L.Y., Y.Z., and D.Z. analyzed the data of experiments and organized figures. P.Y., L.Z., J.N.S., L.Y., L.C., and D.Z. wrote or edited the manuscript.

Peer review

Peer review information

: Nature Communications thanks Anindita Das and the other, anonymous, reviewers for their contribution to the peer review of this work. A peer review file is available.

Data availability

The raw data including bulk RNA sequencing and single-cell RNA sequencing related to the remodeling process generated in this study have been deposited in NCBI’s Gene Expression Omnibus (GEO) under the accession number GSE234717. Raw data for bulk RNA sequencing analysis that revealed the therapeutic mechanism of Y27632/CHIR99021/SB431542 have been deposited in the Genome Sequence Archive under the accession number HRA007850. The single-cell RNA sequencing dataset of human failing heart referenced in this study is available at GSE145154. All data needed to evaluate the conclusions in the paper are present within the paper and/or the Supplementary Information. Source data is available for Fig. 1c, e, f, h; 2b, c, d, g, h; 5f; 6b, c, d; 7b, c, d, f, g; 8c, d, f, and Supplementary Figs. 1f, g; 2b, d, g, i; 3b, c, e, f; 6e; 13b, c, d; 14d, e, f, g, h, i; 15b, c, d, e; 18c; 19c, d, f; 20a, b, d, e, f in the associated source data file. Source data are provided with this paper.

Competing interests

For the development of the hEHT injury model and its application in drug screening, we have been granted a Chinese patent, with inventors Donghui Zhang, Pengcheng Yang, and Jixing Gong, and patent number ZL 2020 1 0620164. X. Besides that, the authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Pengcheng Yang, Lihang Zhu.
==== Refs
References

1. Safiri S Burden of ischemic heart disease and its attributable risk factors in 204 countries and territories, 1990–2019 Eur. J. Prev. Cardiol. 2022 29 420 431 10.1093/eurjpc/zwab213 34922374
Safiri, S. et al. Burden of ischemic heart disease and its attributable risk factors in 204 countries and territories, 1990–2019. Eur. J. Prev. Cardiol. 29, 420–431 (2022).34922374 10.1093/eurjpc/zwab213
2. Nowbar AN Gitto M Howard JP Francis DP Al-Lamee R Mortality from ischemic heart disease Circ. Cardiovasc Qual. Outcomes 2019 12 e005375 10.1161/CIRCOUTCOMES.118.005375 31163980
Nowbar, A. N., Gitto, M., Howard, J. P., Francis, D. P. & Al-Lamee, R. Mortality from ischemic heart disease. Circ. Cardiovasc Qual. Outcomes 12, e005375 (2019).31163980 10.1161/CIRCOUTCOMES.118.005375
3. Pesce M Cardiac fibroblasts and mechanosensation in heart development, health and disease Nat. Rev. Cardiol. 2023 20 309 324 10.1038/s41569-022-00799-2 36376437
Pesce, M. et al. Cardiac fibroblasts and mechanosensation in heart development, health and disease. Nat. Rev. Cardiol. 20, 309–324 (2023).36376437 10.1038/s41569-022-00799-2
4. Piamsiri C Maneechote C Siri-Angkul N Chattipakorn SC Chattipakorn N Targeting necroptosis as therapeutic potential in chronic myocardial infarction J. Biomed. Sci. 2021 28 25 10.1186/s12929-021-00722-w 33836761
Piamsiri, C., Maneechote, C., Siri-Angkul, N., Chattipakorn, S. C. & Chattipakorn, N. Targeting necroptosis as therapeutic potential in chronic myocardial infarction. J. Biomed. Sci. 28, 25 (2021).33836761 10.1186/s12929-021-00722-w
5. de Bakker JM Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlation Circulation 1988 77 589 606 10.1161/01.CIR.77.3.589 3342490
de Bakker, J. M. et al. Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlation. Circulation 77, 589–606 (1988).3342490 10.1161/01.CIR.77.3.589
6. Holmes JW Laksman Z Gepstein L Making better scar: Emerging approaches for modifying mechanical and electrical properties following infarction and ablation Prog. Biophys. Mol. Biol. 2016 120 134 148 10.1016/j.pbiomolbio.2015.11.002 26615948
Holmes, J. W., Laksman, Z. & Gepstein, L. Making better scar: Emerging approaches for modifying mechanical and electrical properties following infarction and ablation. Prog. Biophys. Mol. Biol. 120, 134–148 (2016).26615948 10.1016/j.pbiomolbio.2015.11.002
7. Lian X Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/beta-catenin signaling under fully defined conditions Nat. Protoc. 2013 8 162 175 10.1038/nprot.2012.150 23257984
Lian, X. et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt/beta-catenin signaling under fully defined conditions. Nat. Protoc. 8, 162–175 (2013).23257984 10.1038/nprot.2012.150
8. Zhang H Generation of quiescent cardiac fibroblasts from human induced pluripotent stem cells for in vitro modeling of cardiac fibrosis Circ. Res 2019 125 552 566 10.1161/CIRCRESAHA.119.315491 31288631
Zhang, H. et al. Generation of quiescent cardiac fibroblasts from human induced pluripotent stem cells for in vitro modeling of cardiac fibrosis. Circ. Res. 125, 552–566 (2019).31288631 10.1161/CIRCRESAHA.119.315491
9. Paik DT Large-scale single-cell RNA-Seq reveals molecular signatures of heterogeneous populations of human induced pluripotent stem cell-derived endothelial cells Circ. Res. 2018 123 443 450 10.1161/CIRCRESAHA.118.312913 29986945
Paik, D. T. et al. Large-scale single-cell RNA-Seq reveals molecular signatures of heterogeneous populations of human induced pluripotent stem cell-derived endothelial cells. Circ. Res. 123, 443–450 (2018).29986945 10.1161/CIRCRESAHA.118.312913
10. Shadrin IY Cardiopatch platform enables maturation and scale-up of human pluripotent stem cell-derived engineered heart tissues Nat. Commun. 2017 8 1825 10.1038/s41467-017-01946-x 29184059
Shadrin, I. Y. et al. Cardiopatch platform enables maturation and scale-up of human pluripotent stem cell-derived engineered heart tissues. Nat. Commun. 8, 1825 (2017).29184059 10.1038/s41467-017-01946-x
11. Zhang D Tissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytes Biomaterials 2013 34 5813 5820 10.1016/j.biomaterials.2013.04.026 23642535
Zhang, D. et al. Tissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytes. Biomaterials 34, 5813–5820 (2013).23642535 10.1016/j.biomaterials.2013.04.026
12. Lewis-Israeli YR Self-assembling human heart organoids for the modeling of cardiac development and congenital heart disease Nat. Commun. 2021 12 5142 10.1038/s41467-021-25329-5 34446706
Lewis-Israeli, Y. R. et al. Self-assembling human heart organoids for the modeling of cardiac development and congenital heart disease. Nat. Commun. 12, 5142 (2021).34446706 10.1038/s41467-021-25329-5
13. Hofbauer P Cardioids reveal self-organizing principles of human cardiogenesis Cell 2021 184 3299 3317.e3222 10.1016/j.cell.2021.04.034 34019794
Hofbauer, P. et al. Cardioids reveal self-organizing principles of human cardiogenesis. Cell 184, 3299–3317.e3222 (2021).34019794 10.1016/j.cell.2021.04.034
14. Voges HK Development of a human cardiac organoid injury model reveals innate regenerative potential Development 2017 144 1118 1127 28174241
Voges, H. K. et al. Development of a human cardiac organoid injury model reveals innate regenerative potential. Development 144, 1118–1127 (2017).28174241
15. Richards DJ Human cardiac organoids for the modelling of myocardial infarction and drug cardiotoxicity Nat. Biomed. Eng. 2020 4 446 462 10.1038/s41551-020-0539-4 32284552
Richards, D. J. et al. Human cardiac organoids for the modelling of myocardial infarction and drug cardiotoxicity. Nat. Biomed. Eng. 4, 446–462 (2020).32284552 10.1038/s41551-020-0539-4
16. Polizzotti BD Ganapathy B Haubner BJ Penninger JM Kuhn B A cryoinjury model in neonatal mice for cardiac translational and regeneration research Nat. Protoc. 2016 11 542 552 10.1038/nprot.2016.031 26890681
Polizzotti, B. D., Ganapathy, B., Haubner, B. J., Penninger, J. M. & Kuhn, B. A cryoinjury model in neonatal mice for cardiac translational and regeneration research. Nat. Protoc. 11, 542–552 (2016).26890681 10.1038/nprot.2016.031
17. Hirano A Cryoinjury-induced acute myocardial infarction model and ameroid constrictor-induced ischemic heart disease model in adult micro-mini pigs for preclinical studies Transl. Med. Commun. 2017 2 1 10.1186/s41231-017-0011-y
Hirano, A. et al. Cryoinjury-induced acute myocardial infarction model and ameroid constrictor-induced ischemic heart disease model in adult micro-mini pigs for preclinical studies. Transl. Med. Commun. 2, 1 (2017).10.1186/s41231-017-0011-y
18. Peoples JN Saraf A Ghazal N Pham TT Kwong JQ Mitochondrial dysfunction and oxidative stress in heart disease Exp. Mol. Med 2019 51 1 13 10.1038/s12276-019-0355-7 31857574
Peoples, J. N., Saraf, A., Ghazal, N., Pham, T. T. & Kwong, J. Q. Mitochondrial dysfunction and oxidative stress in heart disease. Exp. Mol. Med. 51, 1–13 (2019).31857574 10.1038/s12276-019-0355-7
19. Talman V Ruskoaho H Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration Cell Tissue Res 2016 365 563 581 10.1007/s00441-016-2431-9 27324127
Talman, V. & Ruskoaho, H. Cardiac fibrosis in myocardial infarction-from repair and remodeling to regeneration. Cell Tissue Res. 365, 563–581 (2016).27324127 10.1007/s00441-016-2431-9
20. Liu M Lopez de Juan Abad B Cheng K Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies Adv. Drug Deliv. Rev. 2021 173 504 519 10.1016/j.addr.2021.03.021 33831476
Liu, M., Lopez de Juan Abad, B. & Cheng, K. Cardiac fibrosis: Myofibroblast-mediated pathological regulation and drug delivery strategies. Adv. Drug Deliv. Rev. 173, 504–519 (2021).33831476 10.1016/j.addr.2021.03.021
21. Bowers SLK Meng Q Molkentin JD Fibroblasts orchestrate cellular crosstalk in the heart through the ECM Nat. Cardiovas. Res. 2022 1 312 321 10.1038/s44161-022-00043-7
Bowers, S. L. K., Meng, Q. & Molkentin, J. D. Fibroblasts orchestrate cellular crosstalk in the heart through the ECM. Nat. Cardiovas. Res. 1, 312–321 (2022).10.1038/s44161-022-00043-7
22. Noordman ABP Myocardial scar characterization and future ventricular arrhythmia in patients with ischemic cardiomyopathy and an implantable cardioverter-defibrillator Front Cardiovasc Med 2021 8 708406 10.3389/fcvm.2021.708406 34485409
Noordman, A. B. P. et al. Myocardial scar characterization and future ventricular arrhythmia in patients with ischemic cardiomyopathy and an implantable cardioverter-defibrillator. Front Cardiovasc Med. 8, 708406 (2021).34485409 10.3389/fcvm.2021.708406
23. Bui AH Waks JW Risk stratification of sudden cardiac death after acute myocardial infarction J. Innov. Card. Rhythm Manag. 2018 9 3035 3049 10.19102/icrm.2018.090201 32477797
Bui, A. H. & Waks, J. W. Risk stratification of sudden cardiac death after acute myocardial infarction. J. Innov. Card. Rhythm Manag. 9, 3035–3049 (2018).32477797 10.19102/icrm.2018.090201
24. Sun J Targeting the metastasis suppressor, NDRG1, using novel iron chelators: regulation of stress fiber-mediated tumor cell migration via modulation of the ROCK1/pMLC2 signaling pathway Mol. Pharm. 2013 83 454 469 10.1124/mol.112.083097
Sun, J. et al. Targeting the metastasis suppressor, NDRG1, using novel iron chelators: regulation of stress fiber-mediated tumor cell migration via modulation of the ROCK1/pMLC2 signaling pathway. Mol. Pharm. 83, 454–469 (2013).10.1124/mol.112.083097
25. Soliman HAN Toso EA Darwish IE Ali SM Kyba M Antiapoptotic Protein FAIM2 is targeted by miR-3202, and DUX4 via TRIM21, leading to cell death and defective myogenesis Cell Death Dis. 2022 13 405 10.1038/s41419-022-04804-x 35468884
Soliman, H. A. N., Toso, E. A., Darwish, I. E., Ali, S. M. & Kyba, M. Antiapoptotic Protein FAIM2 is targeted by miR-3202, and DUX4 via TRIM21, leading to cell death and defective myogenesis. Cell Death Dis. 13, 405 (2022).35468884 10.1038/s41419-022-04804-x
26. Frangogiannis NG Cardiac fibrosis Cardiovasc Res 2021 117 1450 1488 10.1093/cvr/cvaa324 33135058
Frangogiannis, N. G. Cardiac fibrosis. Cardiovasc Res. 117, 1450–1488 (2021).33135058 10.1093/cvr/cvaa324
27. Guo Y Pu WT Cardiomyocyte maturation: new phase in development Circ. Res. 2020 126 1086 1106 10.1161/CIRCRESAHA.119.315862 32271675
Guo, Y. & Pu, W. T. Cardiomyocyte maturation: new phase in development. Circ. Res. 126, 1086–1106 (2020).32271675 10.1161/CIRCRESAHA.119.315862
28. Cagavi E Functional cardiomyocytes derived from Isl1 cardiac progenitors via Bmp4 stimulation PLoS One 2014 9 e110752 10.1371/journal.pone.0110752 25522363
Cagavi, E. et al. Functional cardiomyocytes derived from Isl1 cardiac progenitors via Bmp4 stimulation. PLoS One 9, e110752 (2014).25522363 10.1371/journal.pone.0110752
29. Litvinukova M Cells of the adult human heart Nature 2020 588 466 472 10.1038/s41586-020-2797-4 32971526
Litvinukova, M. et al. Cells of the adult human heart. Nature 588, 466–472 (2020).32971526 10.1038/s41586-020-2797-4
30. Mohamed TMA Regulation of cell cycle to stimulate adult cardiomyocyte proliferation and cardiac regeneration Cell 2018 173 104 116.e112 10.1016/j.cell.2018.02.014 29502971
Mohamed, T. M. A. et al. Regulation of cell cycle to stimulate adult cardiomyocyte proliferation and cardiac regeneration. Cell 173, 104–116.e112 (2018).29502971 10.1016/j.cell.2018.02.014
31. Rao M Resolving the intertwining of inflammation and fibrosis in human heart failure at single-cell level Basic Res. Cardiol. 2021 116 55 10.1007/s00395-021-00897-1 34601654
Rao, M. et al. Resolving the intertwining of inflammation and fibrosis in human heart failure at single-cell level. Basic Res. Cardiol. 116, 55 (2021).34601654 10.1007/s00395-021-00897-1
32. Ko T Cardiac fibroblasts regulate the development of heart failure via Htra3-TGF-beta-IGFBP7 axis Nat. Commun. 2022 13 3275 10.1038/s41467-022-30630-y 35672400
Ko, T. et al. Cardiac fibroblasts regulate the development of heart failure via Htra3-TGF-beta-IGFBP7 axis. Nat. Commun. 13, 3275 (2022).35672400 10.1038/s41467-022-30630-y
33. Cui Y Single-cell transcriptome analysis maps the developmental track of the human heart Cell Rep. 2019 26 1934 1950.e1935 10.1016/j.celrep.2019.01.079 30759401
Cui, Y. et al. Single-cell transcriptome analysis maps the developmental track of the human heart. Cell Rep. 26, 1934–1950.e1935 (2019).30759401 10.1016/j.celrep.2019.01.079
34. Quijada P Coordination of endothelial cell positioning and fate specification by the epicardium Nat. Commun. 2021 12 4155 10.1038/s41467-021-24414-z 34230480
Quijada, P. et al. Coordination of endothelial cell positioning and fate specification by the epicardium. Nat. Commun. 12, 4155 (2021).34230480 10.1038/s41467-021-24414-z
35. Humeres C Smad7 effects on TGF-beta and ErbB2 restrain myofibroblast activation and protect from postinfarction heart failure J. Clin. Invest. 2022 132 e146926 10.1172/JCI146926 34905511
Humeres, C. et al. Smad7 effects on TGF-beta and ErbB2 restrain myofibroblast activation and protect from postinfarction heart failure. J. Clin. Invest. 132, e146926 (2022).34905511 10.1172/JCI146926
36. Knight-Schrijver VR A single-cell comparison of adult and fetal human epicardium defines the age-associated changes in epicardial activity Nat. Cardiovasc. Res. 2022 1 1215 1229 10.1038/s44161-022-00183-w 36938497
Knight-Schrijver, V. R. et al. A single-cell comparison of adult and fetal human epicardium defines the age-associated changes in epicardial activity. Nat. Cardiovasc. Res. 1, 1215–1229 (2022).36938497 10.1038/s44161-022-00183-w
37. Quijada P Trembley MA Small EM The role of the epicardium during heart development and repair Circ. Res. 2020 126 377 394 10.1161/CIRCRESAHA.119.315857 31999538
Quijada, P., Trembley, M. A. & Small, E. M. The role of the epicardium during heart development and repair. Circ. Res. 126, 377–394 (2020).31999538 10.1161/CIRCRESAHA.119.315857
38. Zhou B Pu WT Epicardial epithelial-to-mesenchymal transition in injured heart J. Cell Mol. Med. 2011 15 2781 2783 10.1111/j.1582-4934.2011.01450.x 21914126
Zhou, B. & Pu, W. T. Epicardial epithelial-to-mesenchymal transition in injured heart. J. Cell Mol. Med. 15, 2781–2783 (2011).21914126 10.1111/j.1582-4934.2011.01450.x
39. Cahill TJ Choudhury RP Riley PR Heart regeneration and repair after myocardial infarction: translational opportunities for novel therapeutics Nat. Rev. Drug Discov. 2017 16 699 717 10.1038/nrd.2017.106 28729726
Cahill, T. J., Choudhury, R. P. & Riley, P. R. Heart regeneration and repair after myocardial infarction: translational opportunities for novel therapeutics. Nat. Rev. Drug Discov. 16, 699–717 (2017).28729726 10.1038/nrd.2017.106
40. van Deel ED Extracellular superoxide dismutase protects the heart against oxidative stress and hypertrophy after myocardial infarction Free Radic. Biol. Med. 2008 44 1305 1313 10.1016/j.freeradbiomed.2007.12.007 18206658
van Deel, E. D. et al. Extracellular superoxide dismutase protects the heart against oxidative stress and hypertrophy after myocardial infarction. Free Radic. Biol. Med. 44, 1305–1313 (2008).18206658 10.1016/j.freeradbiomed.2007.12.007
41. Ye Y PON2 ameliorates Ang II-induced cardiomyocyte injury by targeting the CANX/NOX4 signaling pathway Immun. Inflamm. Dis. 2023 11 e765 10.1002/iid3.765 36840500
Ye, Y. et al. PON2 ameliorates Ang II-induced cardiomyocyte injury by targeting the CANX/NOX4 signaling pathway. Immun. Inflamm. Dis. 11, e765 (2023).36840500 10.1002/iid3.765
42. Li C PXDN reduces autophagic flux in insulin-resistant cardiomyocytes via modulating FoxO1 Cell Death Dis. 2021 12 418 10.1038/s41419-021-03699-4 33903591
Li, C. et al. PXDN reduces autophagic flux in insulin-resistant cardiomyocytes via modulating FoxO1. Cell Death Dis. 12, 418 (2021).33903591 10.1038/s41419-021-03699-4
43. Canale P Role of miR-133/Dio3 Axis in the T3-dependent modulation of cardiac mitoK-ATP Expression Int J. Mol. Sci. 2022 23 6549 10.3390/ijms23126549 35742991
Canale, P. et al. Role of miR-133/Dio3 Axis in the T3-dependent modulation of cardiac mitoK-ATP Expression. Int J. Mol. Sci. 23, 6549 (2022).35742991 10.3390/ijms23126549
44. Leyns L Bouwmeester T Kim SH Piccolo S De Robertis EM Frzb-1 is a secreted antagonist of Wnt signaling expressed in the Spemann organizer Cell 1997 88 747 756 10.1016/S0092-8674(00)81921-2 9118218
Leyns, L., Bouwmeester, T., Kim, S. H., Piccolo, S. & De Robertis, E. M. Frzb-1 is a secreted antagonist of Wnt signaling expressed in the Spemann organizer. Cell 88, 747–756 (1997).9118218 10.1016/S0092-8674(00)81921-2
45. Lee H Evans T TMEM88 inhibits Wnt signaling by promoting Wnt signalosome localization to multivesicular bodies iScience 2019 19 267 280 10.1016/j.isci.2019.07.039 31401350
Lee, H. & Evans, T. TMEM88 inhibits Wnt signaling by promoting Wnt signalosome localization to multivesicular bodies. iScience 19, 267–280 (2019).31401350 10.1016/j.isci.2019.07.039
46. Heusch G STAT5 activation and cardioprotection by remote ischemic preconditioning in humans: short communication Circ. Res 2012 110 111 115 10.1161/CIRCRESAHA.111.259556 22116817
Heusch, G. et al. STAT5 activation and cardioprotection by remote ischemic preconditioning in humans: short communication. Circ. Res. 110, 111–115 (2012).22116817 10.1161/CIRCRESAHA.111.259556
47. Cui M Transcription factor NFYa controls cardiomyocyte metabolism and proliferation during mouse fetal heart development Dev. Cell 2023 58 2867 2880.e2867 10.1016/j.devcel.2023.10.012 37972593
Cui, M. et al. Transcription factor NFYa controls cardiomyocyte metabolism and proliferation during mouse fetal heart development. Dev. Cell 58, 2867–2880.e2867 (2023).37972593 10.1016/j.devcel.2023.10.012
48. Milia J Farnesylated RhoB inhibits radiation-induced mitotic cell death and controls radiation-induced centrosome overduplication Cell Death Differ. 2005 12 492 501 10.1038/sj.cdd.4401586 15776002
Milia, J. et al. Farnesylated RhoB inhibits radiation-induced mitotic cell death and controls radiation-induced centrosome overduplication. Cell Death Differ. 12, 492–501 (2005).15776002 10.1038/sj.cdd.4401586
49. Li MJ Upregulation of CCNB2 and its perspective mechanisms in cerebral ischemic stroke and all subtypes of lung cancer: a comprehensive study Front Integr. Neurosci. 2022 16 854540 10.3389/fnint.2022.854540 35928585
Li, M. J. et al. Upregulation of CCNB2 and its perspective mechanisms in cerebral ischemic stroke and all subtypes of lung cancer: a comprehensive study. Front Integr. Neurosci. 16, 854540 (2022).35928585 10.3389/fnint.2022.854540
50. Wang X LOX-1 in the maintenance of cytoskeleton and proliferation in senescent cardiac fibroblasts J. Mol. Cell Cardiol. 2013 60 184 190 10.1016/j.yjmcc.2013.04.024 23648807
Wang, X. et al. LOX-1 in the maintenance of cytoskeleton and proliferation in senescent cardiac fibroblasts. J. Mol. Cell Cardiol. 60, 184–190 (2013).23648807 10.1016/j.yjmcc.2013.04.024
51. Zou Y DNA Hypermethylation of CREB3L1 and Bcl-2 associated with the mitochondrial-mediated apoptosis via PI3K/Akt pathway in human BEAS-2B cells exposure to silica nanoparticles PLoS One 2016 11 e0158475 10.1371/journal.pone.0158475 27362941
Zou, Y. et al. DNA Hypermethylation of CREB3L1 and Bcl-2 associated with the mitochondrial-mediated apoptosis via PI3K/Akt pathway in human BEAS-2B cells exposure to silica nanoparticles. PLoS One 11, e0158475 (2016).27362941 10.1371/journal.pone.0158475
52. Westendorp B E2F7 represses a network of oscillating cell cycle genes to control S-phase progression Nucleic Acids Res. 2012 40 3511 3523 10.1093/nar/gkr1203 22180533
Westendorp, B. et al. E2F7 represses a network of oscillating cell cycle genes to control S-phase progression. Nucleic Acids Res. 40, 3511–3523 (2012).22180533 10.1093/nar/gkr1203
53. Liao R E2F transcription factor 1 (E2F1) promotes the transforming growth factor TGF-beta1 induced human cardiac fibroblasts differentiation through promoting the transcription of CCNE2 gene Bioengineered 2021 12 6869 6877 10.1080/21655979.2021.1972194 34521301
Liao, R. et al. E2F transcription factor 1 (E2F1) promotes the transforming growth factor TGF-beta1 induced human cardiac fibroblasts differentiation through promoting the transcription of CCNE2 gene. Bioengineered 12, 6869–6877 (2021).34521301 10.1080/21655979.2021.1972194
54. Holowiecki A Pbx4 limits heart size and fosters arch artery formation by partitioning second heart field progenitors and restricting proliferation Development 2020 147 dev185652 10.1242/dev.185652 32094112
Holowiecki, A. et al. Pbx4 limits heart size and fosters arch artery formation by partitioning second heart field progenitors and restricting proliferation. Development 147, dev185652 (2020).32094112 10.1242/dev.185652
55. Stellato M The AP-1 transcription factor Fosl-2 drives cardiac fibrosis and arrhythmias under immunofibrotic conditions Commun. Biol. 2023 6 161 10.1038/s42003-023-04534-6 36759717
Stellato, M. et al. The AP-1 transcription factor Fosl-2 drives cardiac fibrosis and arrhythmias under immunofibrotic conditions. Commun. Biol. 6, 161 (2023).36759717 10.1038/s42003-023-04534-6
56. Teekakirikul P Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-beta J. Clin. Invest 2010 120 3520 3529 10.1172/JCI42028 20811150
Teekakirikul, P. et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-beta. J. Clin. Invest 120, 3520–3529 (2010).20811150 10.1172/JCI42028
57. Zhao GJ Yin K Fu YC Tang CK The interaction of ApoA-I and ABCA1 triggers signal transduction pathways to mediate efflux of cellular lipids Mol. Med 2012 18 149 158 10.2119/molmed.2011.00183 22064972
Zhao, G. J., Yin, K., Fu, Y. C. & Tang, C. K. The interaction of ApoA-I and ABCA1 triggers signal transduction pathways to mediate efflux of cellular lipids. Mol. Med. 18, 149–158 (2012).22064972 10.2119/molmed.2011.00183
58. Morikawa Y Heallen T Leach J Xiao Y Martin JF Dystrophin-glycoprotein complex sequesters Yap to inhibit cardiomyocyte proliferation Nature 2017 547 227 231 10.1038/nature22979 28581498
Morikawa, Y., Heallen, T., Leach, J., Xiao, Y. & Martin, J. F. Dystrophin-glycoprotein complex sequesters Yap to inhibit cardiomyocyte proliferation. Nature 547, 227–231 (2017).28581498 10.1038/nature22979
59. Sorensen DW van Berlo JH The role of TGF-beta signaling in cardiomyocyte proliferation Curr. Heart Fail Rep. 2020 17 225 233 10.1007/s11897-020-00470-2 32686010
Sorensen, D. W. & van Berlo, J. H. The role of TGF-beta signaling in cardiomyocyte proliferation. Curr. Heart Fail Rep. 17, 225–233 (2020).32686010 10.1007/s11897-020-00470-2
60. Zhou J The long noncoding RNA THBS1-AS1 promotes cardiac fibroblast activation in cardiac fibrosis by regulating TGFBR1 JCI Insight 2023 8 e160745 10.1172/jci.insight.160745 36787190
Zhou, J. et al. The long noncoding RNA THBS1-AS1 promotes cardiac fibroblast activation in cardiac fibrosis by regulating TGFBR1. JCI Insight 8, e160745 (2023).36787190 10.1172/jci.insight.160745
61. Wang Y Low density lipoprotein receptor related protein 6 (LRP6) protects heart against oxidative stress by the crosstalk of HSF1 and GSK3beta Redox Biol. 2020 37 101699 10.1016/j.redox.2020.101699 32905882
Wang, Y. et al. Low density lipoprotein receptor related protein 6 (LRP6) protects heart against oxidative stress by the crosstalk of HSF1 and GSK3beta. Redox Biol. 37, 101699 (2020).32905882 10.1016/j.redox.2020.101699
62. Yang H Deriving waveform parameters from calcium transients in human iPSC-derived cardiomyocytes to predict cardiac activity with machine learning Stem Cell Rep. 2022 17 556 568 10.1016/j.stemcr.2022.01.009
Yang, H. et al. Deriving waveform parameters from calcium transients in human iPSC-derived cardiomyocytes to predict cardiac activity with machine learning. Stem Cell Rep. 17, 556–568 (2022).10.1016/j.stemcr.2022.01.009
63. Peck KA Extracellular vesicles secreted by TDO2-augmented fibroblasts regulate pro-inflammatory response in macrophages Front Cell Dev. Biol. 2021 9 733354 10.3389/fcell.2021.733354 34751245
Peck, K. A. et al. Extracellular vesicles secreted by TDO2-augmented fibroblasts regulate pro-inflammatory response in macrophages. Front Cell Dev. Biol. 9, 733354 (2021).34751245 10.3389/fcell.2021.733354
64. Kaur A ChaC2, an enzyme for slow turnover of cytosolic glutathione J. Biol. Chem. 2017 292 638 651 10.1074/jbc.M116.727479 27913623
Kaur, A. et al. ChaC2, an enzyme for slow turnover of cytosolic glutathione. J. Biol. Chem. 292, 638–651 (2017).27913623 10.1074/jbc.M116.727479
65. Pei H G protein-coupled estrogen receptor 1 inhibits angiotensin II-induced cardiomyocyte hypertrophy via the regulation of PI3K-Akt-mTOR signalling and autophagy Int J. Biol. Sci. 2019 15 81 92 10.7150/ijbs.28304 30662349
Pei, H. et al. G protein-coupled estrogen receptor 1 inhibits angiotensin II-induced cardiomyocyte hypertrophy via the regulation of PI3K-Akt-mTOR signalling and autophagy. Int J. Biol. Sci. 15, 81–92 (2019).30662349 10.7150/ijbs.28304
66. Duval V Alayrac P Silvestre JS Levoye A Emerging roles of the atypical chemokine receptor 3 (ACKR3) in cardiovascular diseases Front Endocrinol. (Lausanne) 2022 13 906586 10.3389/fendo.2022.906586 35846294
Duval, V., Alayrac, P., Silvestre, J. S. & Levoye, A. Emerging roles of the atypical chemokine receptor 3 (ACKR3) in cardiovascular diseases. Front Endocrinol. (Lausanne) 13, 906586 (2022).35846294 10.3389/fendo.2022.906586
67. Cadenas S Mitochondrial uncoupling, ROS generation and cardioprotection Biochim Biophys. Acta Bioenerg. 2018 1859 940 950 10.1016/j.bbabio.2018.05.019 29859845
Cadenas, S. Mitochondrial uncoupling, ROS generation and cardioprotection. Biochim Biophys. Acta Bioenerg. 1859, 940–950 (2018).29859845 10.1016/j.bbabio.2018.05.019
68. Cai W Alox15/15-HpETE aggravates myocardial ischemia-reperfusion injury by promoting cardiomyocyte ferroptosis Circulation 2023 147 1444 1460 10.1161/CIRCULATIONAHA.122.060257 36987924
Cai, W. et al. Alox15/15-HpETE aggravates myocardial ischemia-reperfusion injury by promoting cardiomyocyte ferroptosis. Circulation 147, 1444–1460 (2023).36987924 10.1161/CIRCULATIONAHA.122.060257
69. Voros I Somatostatin and its receptors in myocardial ischemia/reperfusion injury and cardioprotection Front Pharm. 2021 12 663655 10.3389/fphar.2021.663655
Voros, I. et al. Somatostatin and its receptors in myocardial ischemia/reperfusion injury and cardioprotection. Front Pharm. 12, 663655 (2021).10.3389/fphar.2021.663655
70. Natarajan N Complement receptor C5aR1 plays an evolutionarily conserved role in successful cardiac regeneration Circulation 2018 137 2152 2165 10.1161/CIRCULATIONAHA.117.030801 29348261
Natarajan, N. et al. Complement receptor C5aR1 plays an evolutionarily conserved role in successful cardiac regeneration. Circulation 137, 2152–2165 (2018).29348261 10.1161/CIRCULATIONAHA.117.030801
71. Lindsey ML Assigning matrix metalloproteinase roles in ischaemic cardiac remodelling Nat. Rev. Cardiol. 2018 15 471 479 10.1038/s41569-018-0022-z 29752454
Lindsey, M. L. Assigning matrix metalloproteinase roles in ischaemic cardiac remodelling. Nat. Rev. Cardiol. 15, 471–479 (2018).29752454 10.1038/s41569-018-0022-z
72. Meng F Martin JF Embryonic ECM Protein SLIT2 and NPNT promote postnatal cardiomyocyte cytokinesis Circ. Res. 2020 127 908 910 10.1161/CIRCRESAHA.120.317798 32910739
Meng, F. & Martin, J. F. Embryonic ECM Protein SLIT2 and NPNT promote postnatal cardiomyocyte cytokinesis. Circ. Res. 127, 908–910 (2020).32910739 10.1161/CIRCRESAHA.120.317798
73. Zhou Y Single-cell transcriptomic analyses of cell fate transitions during human cardiac reprogramming Cell Stem Cell 2019 25 149 164.e149 10.1016/j.stem.2019.05.020 31230860
Zhou, Y. et al. Single-cell transcriptomic analyses of cell fate transitions during human cardiac reprogramming. Cell Stem Cell 25, 149–164.e149 (2019).31230860 10.1016/j.stem.2019.05.020
74. Asaumi Y Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice Circulation 2007 115 2022 2032 10.1161/CIRCULATIONAHA.106.659037 17404160
Asaumi, Y. et al. Protective role of endogenous erythropoietin system in nonhematopoietic cells against pressure overload-induced left ventricular dysfunction in mice. Circulation 115, 2022–2032 (2007).17404160 10.1161/CIRCULATIONAHA.106.659037
75. Lam NT Sadek HA Neonatal heart regeneration: comprehensive literature review Circulation 2018 138 412 423 10.1161/CIRCULATIONAHA.118.033648 30571359
Lam, N. T. & Sadek, H. A. Neonatal heart regeneration: comprehensive literature review. Circulation 138, 412–423 (2018).30571359 10.1161/CIRCULATIONAHA.118.033648
76. Pillai ICL Cardiac fibroblasts adopt osteogenic fates and can be targeted to attenuate pathological heart calcification Cell Stem Cell 2017 20 218 232.e215 10.1016/j.stem.2016.10.005 27867037
Pillai, I. C. L. et al. Cardiac fibroblasts adopt osteogenic fates and can be targeted to attenuate pathological heart calcification. Cell Stem Cell 20, 218–232.e215 (2017).27867037 10.1016/j.stem.2016.10.005
77. Giacomotto J Segalat L High-throughput screening and small animal models, where are we? Br. J. Pharm. 2010 160 204 216 10.1111/j.1476-5381.2010.00725.x
Giacomotto, J. & Segalat, L. High-throughput screening and small animal models, where are we? Br. J. Pharm. 160, 204–216 (2010).10.1111/j.1476-5381.2010.00725.x
78. Ubil E Mesenchymal-endothelial transition contributes to cardiac neovascularization Nature 2014 514 585 590 10.1038/nature13839 25317562
Ubil, E. et al. Mesenchymal-endothelial transition contributes to cardiac neovascularization. Nature 514, 585–590 (2014).25317562 10.1038/nature13839
79. Koenig AL Single-cell transcriptomics reveals cell-type-specific diversification in human heart failure Nat. Cardiovasc Res 2022 1 263 280 10.1038/s44161-022-00028-6 35959412
Koenig, A. L. et al. Single-cell transcriptomics reveals cell-type-specific diversification in human heart failure. Nat. Cardiovasc Res. 1, 263–280 (2022).35959412 10.1038/s44161-022-00028-6
80. Kanisicak O Genetic lineage tracing defines myofibroblast origin and function in the injured heart Nat. Commun. 2016 7 12260 10.1038/ncomms12260 27447449
Kanisicak, O. et al. Genetic lineage tracing defines myofibroblast origin and function in the injured heart. Nat. Commun. 7, 12260 (2016).27447449 10.1038/ncomms12260
81. Dong LY Qiu XX Zhuang Y Xue S Y-27632, a Rho-kinase inhibitor, attenuates myocardial ischemia-reperfusion injury in rats Int J. Mol. Med 2019 43 1911 1919 30816436
Dong, L. Y., Qiu, X. X., Zhuang, Y. & Xue, S. Y-27632, a Rho-kinase inhibitor, attenuates myocardial ischemia-reperfusion injury in rats. Int J. Mol. Med. 43, 1911–1919 (2019).30816436
82. Zhao M Y-27632 preconditioning enhances transplantation of human-induced pluripotent stem cell-derived cardiomyocytes in myocardial infarction mice Cardiovasc Res 2019 115 343 356 10.1093/cvr/cvy207 30107391
Zhao, M. et al. Y-27632 preconditioning enhances transplantation of human-induced pluripotent stem cell-derived cardiomyocytes in myocardial infarction mice. Cardiovasc Res. 115, 343–356 (2019).30107391 10.1093/cvr/cvy207
83. Xu Y A transient wave of Bhlhe41(+) resident macrophages enables remodeling of the developing infarcted myocardium Cell Rep. 2023 42 113174 10.1016/j.celrep.2023.113174 37751357
Xu, Y. et al. A transient wave of Bhlhe41(+) resident macrophages enables remodeling of the developing infarcted myocardium. Cell Rep. 42, 113174 (2023).37751357 10.1016/j.celrep.2023.113174
84. Mills RJ Functional screening in human cardiac organoids reveals a metabolic mechanism for cardiomyocyte cell cycle arrest Proc. Natl Acad. Sci. USA 2017 114 E8372 E8381 10.1073/pnas.1707316114 28916735
Mills, R. J. et al. Functional screening in human cardiac organoids reveals a metabolic mechanism for cardiomyocyte cell cycle arrest. Proc. Natl Acad. Sci. USA 114, E8372–E8381 (2017).28916735 10.1073/pnas.1707316114
85. Ruan H Single-cell reconstruction of differentiation trajectory reveals a critical role of ETS1 in human cardiac lineage commitment BMC Biol. 2019 17 89 10.1186/s12915-019-0709-6 31722692
Ruan, H. et al. Single-cell reconstruction of differentiation trajectory reveals a critical role of ETS1 in human cardiac lineage commitment. BMC Biol. 17, 89 (2019).31722692 10.1186/s12915-019-0709-6
86. Hall C Chronic activation of human cardiac fibroblasts in vitro attenuates the reversibility of the myofibroblast phenotype Sci. Rep. 2023 13 12137 10.1038/s41598-023-39369-y 37495732
Hall, C. et al. Chronic activation of human cardiac fibroblasts in vitro attenuates the reversibility of the myofibroblast phenotype. Sci. Rep. 13, 12137 (2023).37495732 10.1038/s41598-023-39369-y
87. Frangogiannis NG Transforming growth factor-beta in myocardial disease Nat. Rev. Cardiol. 2022 19 435 455 10.1038/s41569-021-00646-w 34983937
Frangogiannis, N. G. Transforming growth factor-beta in myocardial disease. Nat. Rev. Cardiol. 19, 435–455 (2022).34983937 10.1038/s41569-021-00646-w
88. Miyaoka Y Isolation of single-base genome-edited human iPS cells without antibiotic selection Nat. Methods 2014 11 291 293 10.1038/nmeth.2840 24509632
Miyaoka, Y. et al. Isolation of single-base genome-edited human iPS cells without antibiotic selection. Nat. Methods 11, 291–293 (2014).24509632 10.1038/nmeth.2840
89. Li L Generation of high-performance human cardiomyocytes and engineered heart tissues from extended pluripotent stem cells Cell Discov. 2022 8 105 10.1038/s41421-022-00446-7 36220833
Li, L. et al. Generation of high-performance human cardiomyocytes and engineered heart tissues from extended pluripotent stem cells. Cell Discov. 8, 105 (2022).36220833 10.1038/s41421-022-00446-7
90. Zhang D Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells Cell Res 2009 19 429 438 10.1038/cr.2009.28 19255591
Zhang, D. et al. Highly efficient differentiation of human ES cells and iPS cells into mature pancreatic insulin-producing cells. Cell Res. 19, 429–438 (2009).19255591 10.1038/cr.2009.28
91. Park SJ Insights into the pathogenesis of catecholaminergic polymorphic ventricular tachycardia from engineered human heart tissue Circulation 2019 140 390 404 10.1161/CIRCULATIONAHA.119.039711 31311300
Park, S. J. et al. Insights into the pathogenesis of catecholaminergic polymorphic ventricular tachycardia from engineered human heart tissue. Circulation 140, 390–404 (2019).31311300 10.1161/CIRCULATIONAHA.119.039711
92. Pei J LPA(2) contributes to vascular endothelium homeostasis and cardiac remodeling after myocardial infarction Circ. Res 2022 131 388 403 10.1161/CIRCRESAHA.122.321036 35920162
Pei, J. et al. LPA(2) contributes to vascular endothelium homeostasis and cardiac remodeling after myocardial infarction. Circ. Res. 131, 388–403 (2022).35920162 10.1161/CIRCRESAHA.122.321036
93. Remes A Adapted clustering method for generic analysis of histological fibrosis staining as an open source tool Sci. Rep. 2023 13 4389 10.1038/s41598-023-30196-9 36928369
Remes, A. et al. Adapted clustering method for generic analysis of histological fibrosis staining as an open source tool. Sci. Rep. 13, 4389 (2023).36928369 10.1038/s41598-023-30196-9
94. Yu C An intrapericardial injectable hydrogel patch for mechanical-electrical coupling with infarcted myocardium ACS Nano 2022 16 16234 16248 10.1021/acsnano.2c05168 36190461
Yu, C. et al. An intrapericardial injectable hydrogel patch for mechanical-electrical coupling with infarcted myocardium. ACS Nano 16, 16234–16248 (2022).36190461 10.1021/acsnano.2c05168
95. Butler A Hoffman P Smibert P Papalexi E Satija R Integrating single-cell transcriptomic data across different conditions, technologies, and species Nat. Biotechnol. 2018 36 411 420 10.1038/nbt.4096 29608179
Butler, A., Hoffman, P., Smibert, P., Papalexi, E. & Satija, R. Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat. Biotechnol. 36, 411–420 (2018).29608179 10.1038/nbt.4096
96. Aran D Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage Nat. Immunol. 2019 20 163 172 10.1038/s41590-018-0276-y 30643263
Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163–172 (2019).30643263 10.1038/s41590-018-0276-y
97. Aibar S SCENIC: single-cell regulatory network inference and clustering Nat. Methods 2017 14 1083 1086 10.1038/nmeth.4463 28991892
Aibar, S. et al. SCENIC: single-cell regulatory network inference and clustering. Nat. Methods 14, 1083–1086 (2017).28991892 10.1038/nmeth.4463
98. Trapnell C The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells Nat. Biotechnol. 2014 32 381 386 10.1038/nbt.2859 24658644
Trapnell, C. et al. The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells. Nat. Biotechnol. 32, 381–386 (2014).24658644 10.1038/nbt.2859
99. Efremova M Vento-Tormo M Teichmann SA Vento-Tormo R CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes Nat. Protoc. 2020 15 1484 1506 10.1038/s41596-020-0292-x 32103204
Efremova, M., Vento-Tormo, M., Teichmann, S. A. & Vento-Tormo, R. CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes. Nat. Protoc. 15, 1484–1506 (2020).32103204 10.1038/s41596-020-0292-x
